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ABSTRACT 
 
Cytochrome P450 3A4 (CYP3A4) plays a central role in xenobiotic metabolism, 
and is of critical importance to both human health and the pharmaceutical industry.  Its 
ability to interact with multiple molecules of the same substrate, or multiple substrates, 
leads to complex non-Michaelis kinetics, called “homotropic” and “heterotropic” 
cooperativity respectively.  Significant progress has been made towards understanding 
the enzyme’s complex kinetics by work in our laboratory to isolate the enzyme in 
Nanodiscs.  This provides a homogenous, monodisperse, native-like environment, 
where the monomeric enzyme is biophysically characterized in the absence of 
detergent micellar mixtures or liposomal systems which are reported to lead to enzyme 
heterogeneity and obfuscate its kinetic behavior. 
Three distinct observable properties which CYP3A4 displays as a result of its 
reaction cycle are:  heme iron spin state, NADPH oxidation rate, and product formation 
rate.  Measuring these three observables as a function of substrate concentration and 
simultaneously fitting the data sets to a model results in a global analysis of the 
enzyme’s properties.  It reveals the source of homotropic atypical kinetics is not due to 
any binding cooperativity between the substrates, but rather differences in magnitude of 
the functional properties from the various enzyme-substrate complexes in solution. 
To extend this analysis to better understand heterotropic interactions in the 
system, we generate an interaction surface based upon the linear combination of two 
substrates kinetic profiles, which corresponds to the absence of any specific 
heterotropic interactions between them.  By comparing the observed behavior of the 
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mixed substrate system to that of the model, we show how two commonly reported 
heterotropic substrates of CYP3A4 are actually not cooperative, and the observed 
cooperativity is due to differences in the amplitudes of the functional properties from the 
various binding intermediates in the system which give rise to the overall observed 
behavior of the enzyme.  
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CHAPTER ONE:  INTRODUCTION 
 
1.1 Cytochrome P450 Monoxygenases:  Discovery and Nomenclature 
Cytochrome P450 monoxygenases represent a diverse superfamily of heme 
enzymes observed in all kingdoms of life.  Discovered by Garfinkel and Klingeneberg in 
1958 (1-2)  who isolated a novel pigment with a large absorbance peak at 450 nm when 
reduced with sodium hydrosulfite and saturated with carbon monoxide while studying rat 
and pig liver pigments.  The pigment was further isolated and quantitatively 
characterized by Omura and Sato (3-4), leading to the discovery of a new superfamily of 
enzymes now known as the cytochromes P450.  The cytochrome P450 mechanism 
utilizes atmospheric oxygen two electrons from NAD(P)H and two protons from the 
solvent water to from the active ferryl-oxo intermediate, termed compound I. 
The number of cytochromes P450 has grown exponentially as genome 
sequencing has become more common.  As of Febrauary 2011 over 12,500 sequences 
have been identified encompassing over 950 families and over 2500 subfamilies.  
Cytochromes P450 are divided into families and subfamilies based on primary amino 
acid sequence identity (5-10).  Families share 40% amino acid identity denoted by the 
first number.  The following letter denotes the subfamily designation and a 55% amino 
acid identity between members.  The subfamilies are then broken down into individual 
loci represented by a second number (5-6).
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The number of cytochromes P450 identified in various organisms’ genomes 
varies widely.  In the single-celled photosynthetic organism Chlamydomonas there are 
41 putative cytochrome P450 genes, 20 in the microbe Mycobacterium tuberculosis, 57 
in Homo sapiens (human), 90 in Drosophilia meloganster (fruit fly), 103 in Mus 
musculus (mouse), and 83 in Caenorhabditis elegans (roundworm) (11-13).  Higher 
plants generally have a larger number of cytochrome P450 genes – for example, there 
are 289 identified P450 genes in Arabidopsis thaliana and 182 in Carica papaya 
(papaya) (8, 14 , 15). 
 
1.2 General Structure and Function of Cytochromes P450 
All cytochromes P450, whether soluble or membrane associated, contain one 
heme b (protoporphyrin IX) buried within protein globule which is coordinated with the 
thiolate sulfur atom of cysteine as the fifth axial ligand.  The protein globule, which 
ranges between 45-60 kDa and shares a common P450 fold across the members of the 
superfamily (16).  The helices are labeled A through L, though some isozymes have the 
additional B’, F’, G’, J’ and K’ helices, see figure 1.1.  The loop at the N-terminus of the 
L-helix contains the absolutely conserved cysteine which serves as the ligand for the 
heme iron.  Amide groups from three highly conserved neighboring residues serve to 
form hydrogen bonds with the sulfur atom, which raise the redox potential of the 
cytochrome P450 into the accessible physiological range for the NAD(P)H reductant.  
This leads to the most characteristic P450 consensus sequence, Phe-X-XGly-X-Arg-X-
Cys-X-Gly, in the heme binding loop (17).  The other conserved sequence in the I helix, 
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Ala/Gly-Gly-X-Asp/Glu-Thr-Thr/Ser, forms a kink in the helical structure which is 
believed to position side-chains to stabilize water molecules that are involved in proton 
delivery during the formation of Compound 0 and Compound I (18).  The other 
conserved Glu-X-X-Arg motif located in the K helix likely helps form the core structure 
(17).  Helices B, B’, F, F’, G’ and G, along with their connecting loops are involved in 
substrate binding and are generally more flexible, and vary in length depending upon 
the isozyme.  Comparison of X-ray structures with and without substrate bound have 
shown these helices undergo large scale conformational changes to accommodate 
substrate binding, as first observed using a modified substrate in CYP101 to trap the 
(P450cam) ‘open’ state (19). 
 
Figure 1.1 Crystal Structure of CYP3A4.  The heme is shown in purple, the helices in 
red, and the membrane bilayer is represented by the blue line. 
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 Cytochromes P450 can generally be divided into performing one of two 
physiological roles:  metabolic synthesis of important biological molecules and the 
catabolic breakdown of xenobiotics.  Single celled microbes such as bacteria and 
archaea use the cytochromes P450 to adapt to their environment and to manufacture 
signaling molecules.  Most multicellular organisms use them for cellular signaling and 
some for manufacturing toxins as a defense (14, 20), while some use them to 
metabolize these toxins, and other toxins encountered in the environment (14, 21-22). 
 Cytochromes P450 are ubiquitous because they are able to catalyze many 
diverse reactions, diagramed in figure 1.2.  Secondary structural elements with a 
common protein fold facilitate a diverse set of chemical reactions on a wide range of 
substrates by changing the substrate recognition event (16).  The most commonly 
studied reaction of cytochromes P450 is substrate hydroxylation, which was been 
studied extensively in CYP101A1 (23-25).  Other reactions performed by the 
superfamily include dealkylation, epoxidation, dehydrogenation, carbon-carbon (C-C) 
bond cleavage (26-27). 
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Figure 1.2 Chemical Reactions of Cytochromes P450.  Adapted from Makris et al.  
2004 
 
1.3 Cytochrome P450 Reduction Mechanism 
 There are two main classes of cytochromes P450, the first accepts electrons 
from an iron-sulfur protein, which in turn receives the electrons from a partnering flavin-
containing reductase protein.  The reductase protein utilizes NAD(P)H to receive two 
electrons and transfer them to the ferrodoxin in two one electron transfers.  The second 
class of cytochromes P450 consist of  a single diflavin-containing reductase protein that 
contains both an FMN and a FAD domain, which can shuttle electrons between NADPH 
and the heme iron of the P450 for substrate metabolism through a cyclical quinone and 
semi-quinone transfer (28-29).  These cytochromes P450 are usually membrane 
associated, as are their reductase redox partners. 
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 There are several cytochromes P450 that do not fit into either class using 
reducing equivalents from NADPH, NADH or pyruvic acid.  CYP102 (P450 BM-3) is a 
soluble isozyme from Bacillus megaterium which catalyzes a hydroxylation of fatty acids 
at several non-terminal positions (30-33).  This P450 has been shown to catalyze fatty 
acid hydroxylations at a rate up to 15000 min-1 (34).  The enzyme contains both a heme 
domain similar to those found in other cytochromes P450, and a reductase domain that 
is similar to an FMN and FAD containing reductase, utilized by the second class 
enzymes.  These two domains are fused together though a small peptide linker (35).  
Recent studies have shown that the reductase domain by itself, expressed 
recombinantly, retains its ability to interact with and reduce other class 2 enzymes such 
CYP3A4, although more slowly than their native reductase redox partner (36-37). 
Several other cytochrome P450 classes exist catalyzing a variety of reactions 
using an assortment of reducing equivalents.  Cytochrome P450 RhF from 
Rhodococcus sphaeroides is an example of a class comprised of a fusion of three 
domains, an iron sulfur protein (similar to class 1) and an FMN reductase domain that 
utilizes NADH for its electrons (38-39).  In another class the enzyme can directly utilize 
reducing equivalents from NADH in solution, without the need for accessory proteins.  
An example is cytochrome P450nor from Fusarium oxysporum, which catalyzes the 
conversion of nitric oxide to nitrous oxide (40).  Another example is cytochrome P450 
119A2, from a thermoacidophilic crenarchaeon, which can catalyze styrene epoxidation 
using NADH or NADPH as an electron donor in the absence of a redox partner (41).  
Additionally, CYP119 has been isolated from Sulfolobus solfataricus, and this enzyme 
can use pyruvic acid as the reducing equivalents, which are shuttled through the redox 
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partner and metabolizing substrate such as lauric acid (42).  It was using this isozyme 
that the highly reactive Compound I state of the reactive cycle was first observed (43-
44), which will be discussed in the following section. 
Additionally, a reconstituted in vitro system has been developed to perform light 
driven P450 reactions using photosystem I to generate reducing equivalents and 
ferredoxin as the electron carrier to cytochrome P450 79A1 (45).  Although this is not a 
naturally occurring system, the use of light to substitute for NAD(P)H offers an 
alternative approach for the in vitro synthesis of bioactive compounds. 
 
1.4 The P450 Reaction Cycle 
Cytochromes P450 progress through a common catalytic cycle to activate 
molecular oxygen and incorporate a single oxygen atom into their substrates, as 
detailed in the figure 1.3 below (46).  Beginning in the resting state at the top of the 
figure the enzyme has a water molecule bound at the sixth coordination position, and 
the ferric heme is in the low spin state (the five d-shell electrons in the S=1/2 
configuration).  Binding of the substrate perturbs the ligand field, displacing the water 
molecule, and results in a re-configuration of the d-shell electrons to a high spin (S=5/2) 
state.  This produces the observable Type-I spectral change.  This is followed by the 
delivery of an electron, causing the reduction of the heme iron to the ferrous state, 
through one of mechanisms described in section 1.3.  Next, oxygen binds to the ferrous 
heme forming the ferrous-dioxygen adduct.  This intermediate may autoxidize releasing 
superoxide and regenerating the ferric protein.  Otherwise, a second electron is 
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delivered forming a heme bound peroxo anion, and is followed by the delivery of a 
proton forming the hydroperoxo intermediate.  “Compound 0” (Cpd 0) may refer to either 
the protonated or unprotonated iron-peroxo complex.  This intermediate serves as a 
branch point for either the non-productive release of peroxide or the delivery of a 
second proton to the distal oxygen.  The delivery of the second proton causes O-O 
bond scission and results in the release of water and the formation of the higher valent 
ferryl-oxy complex, with a pi-cation radical on the porphyrin; referred to as “Compound I” 
(Cpd I) or the ferryl-oxo state.  Cpd I can transfer the oxygen atom to the bound 
substrate, or undergo a further two electron reduction, leading to the formation of a 
second water molecule.  Dissociation of the product returns the enzyme to the ferric 
resting state completing the cycle. 
 
Figure 1.3 The Cytochrome P450 Reaction Cycle.  Adapted from Denisov et al. 2005. 
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1.5 Human Cytochromes P450 
 There are 57 known cytochromes P450 in the human, though others may be 
present due to alternate splicing events (11, 21).  Cytochromes P450 are responsible 
for several key aspects of human homeostasis including both anabolic and catabolic 
metabolism. The metabolism of drugs, vitamin A, steroids, fatty acids, and 
prostaglandins, are all pathways which include cytochromes P450.  Human 
cytochromes P450 are usually located in the endoplasmic reticulum or the mitochondria 
of the target tissue, such as the liver, lungs, brain, or reproductive tissues (21).  
1.5.1 Drug Metabolizing Cytochromes P450 
 There are eleven major drug metabolizing cytochromes P450 in the adult human 
body.  All are promiscuous enzymes with broad substrate specificity which leads to 
some overlap in substrates between the isozymes (47).  Their prominent role in drug 
metabolism leads to several different considerations during pharmaceutical 
development.  The expression levels of cytochromes P450 in the liver vary dramatically 
among populations.  For the main hepatic drug metabolizing enzymes, which include 
1A2, 2A6, 2B6, 2C9 2D6, 2E1, and 3A4, the difference can be as much as 0.43 nmol of 
P450 per mg of liver protein in Caucasians versus 0.26 nmol of P450 per mg of liver 
protein in the Japanese potentially resulting in these populations having different 
metabolic profiles for specific drugs (48).   
 Another aspect of human drug clearance is the differential hepatic cytochromes 
P450 allelic variation and genetic polymorphisms. In the late 1950s and early 1960s 
clinicians coined terms for individuals who were out of the norm for metabolizing the 
10 
 
pharmaceuticals:  poor, extensive, and ultra metabolizers (49-51).  As the drug 
metabolizing cytochromes P450 became better understood, it was discovered that 
these categories stem mostly from genetic variation in cytochrome P450 genes.  The 
common problems found in Poor Metabolizers include frame shifts, single nucleotide 
deletions, and mRNA misplicing events (50, 52-53).  Among Northern Europeans, 97% 
of Poor Metabolizers can be traced to four allelic variations in different classes of 
cytochromes P450 (54-57).  The Ultra Metabolizer category is due mostly to gene 
duplication of specific cytochromes P450 (58), but it may also be caused by defective 
regulatory control of gene transcription (21).   
 Other aspects of human cytochromes P450 are the toxicology and cancer risks 
associated with the bioactivation of potentially harmful compounds and their precursors.  
Acetaminophen and the insecticide parathion have been shown to be bioactivated by 
cytochromes P450 (59-61), which leads to liver toxicity and poisoning.  
There is a well-established link between glaucoma and a truncated form of 
CYP1B1 (62), though the reason is still uncertain.  Other links between hepatic P450s 
and disease, such as CYP1A2 and colon cancer (63) and between CYP2A6 and lung 
cancer (64).  Some of these are simply the bioactivation of environmental chemicals 
that lead to cytotoxicity and DNA damage.  The differential expression of P450s can 
lead to individual sensitivity to different chemicals and environmental factors, providing 
a further level of complexity to the toxicological role played by these enzymes (65). 
 An important factor in the role of the human drug metabolizing cytochromes P450 
is the broad substrate set that they may recognize and metabolize.  This lack of 
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substrate specificity allows for a variety of substrates to bind and be metabolized by any 
given cytochrome P450, and the same substrate can be metabolized by multiple 
isozymes of cytochrome P450 (47, 66).  Drug metabolizing enzymes, which reside 
mainly in the liver and kidney, can be responsible for drug-drug interactions or other 
side effects, sometimes to leading the removal of an efficacious compound from the 
market due to toxic metabolites (67-69).  These enzymes are of critical importance to 
pharmaceutical companies, as an understanding of the complex metabolites of these 
enzymes can mean the difference between the success and failure of a given drug, and 
millions of dollars.  The study of drug metabolizing enzymes and how they function was 
in part of the motivation behind the work described in this thesis.   
1.5.2 Cytochrome P450 3A4 
 CYP3A4 is the key drug metabolizing enzyme in the human liver, although it is 
also found in the small intestine, lungs, brain, stomach and colon (21).  CYP3A4 
accounts for as much as 25-30% of the total cytochrome P450 in the liver (70), and in 
specific cases can increase to as much as 60% of the total P450 population (71).  In 
other tissues, such as the small intestine, CYP3A4 can account for around 60% of the 
P450 population (71-72).  CYP3A4 is expressed primarily in adults, while in fetal tissues 
the isozyme CYP3A7 predominates and little CYP3A4 is expressed (73).  The 
expression of CYP3A4 is 50% compared to that of adults within 6 to 12 months after 
birth.  There are also no known gender differences in the expression of CYP3A4 (48). 
 The CYP3A4 gene is located on chromosome 7q22.1 (74) and was originally 
found to be inducible by multiple different classes of pharmaceuticals, including 
barbiturates and macrolide antibiotics (75); but there was limited direct correlation of 
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action (76-78).  More recently studies have linked CYP3A4 expression to PXR, a steroid 
family receptor.  This receptor has been shown to activate CYP3A4 transcription and 
the production of CYP3A4 mRNA (79-80).  The vitamin D receptor class has been 
shown to downregulate the transcription of CYP3A4 (81), as has ketoconazole, a 
common antifungal drug (82).  It is interesting to note that ketoconazole also specifically 
inhibits CYP3A4 protein by ligating the heme iron, leading to several competing 
mechanisms for ketoconazole inhibition (83).  Other pharmaceuticals that inhibit the 
transcription of CYP3A4 include erythromycin and other amine antibiotics (84). 
 Once CYP3A4 is translated and has metabolized substrates, it is targeted for 
destruction by specific phosphorylations at Thr264 and Ser420 by protein kinase C (85).  
The first step to the ubiqutination pathway and final destruction of the enzyme, and is 
thought to target CYP3A4 to a proteasome for degradation (86).  However, this pathway 
remains to be fully elucidated. 
 CYP3A4 is known to metabolize almost 50% of the pharmaceuticals on the 
market today (87).  The diversity of substrate specificity for CYP3A4 is so great that it 
has not only substrates, but also classes of known inducers and inhibitors (88). 
Examples of inducers include St. John’s wort, barbiturates, rifampin, and 
carbamazepine, all of which stimulate the metabolic rates of other substrates (88).  
Inhibitors of CYP3A4 include indinavir, saquinavir, ciprofloxacin, erythromycin, 
gestodene, verapamil, and fluconazole (78, 88).  For a comprehensive list of CYP3A4 
substrates, inhibitors, and inducers (a list which includes >1000 substrates and 
chemical reactivities for CYP3A4, as well as the other xenobiotic metabolizing 
cytochromes P450) refer to Rendic’s 2002 review (88).  These classes of drugs include 
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HIV anti-retrovirals, cholesterol lowering drugs (statins), antifungals (azoles), antibiotics 
(erythromycin), and dietary supplements (St. John ’s wort).  From the number of 
potential interactions it is clear why a detailed understanding of this enzyme is important 
(78, 89). 
CYP3A4 was first studied as a mixture with other cytochromes P450 using liver 
microsomes, which were known to metabolize many endogenous and xenobiotic 
compounds (90-94).  When studying the pharmacological effects of CYP3A4 from liver 
tissue in vitro, there is always the concern that the effects seen could be caused by one 
of the other ten P450 isozymes in the liver.  While CYP3A4 is the major enzyme in liver 
tissue, studies have also shown these enzymes to be cross reactive (95-97).  For any 
given substrate, there are often two or possibly three isozymes that can metabolize it at 
various positions (98).  While liver microsomes yield insights about metabolism on a 
physiological level, it only provides a limited understanding of the function of any 
individual P450.  The advent of recombinant DNA technologies has allowed for the 
expression of a single cytochrome P450 in an organism for study.  With CYP3A4, this 
was first accomplished with a full-length CYP3A4 gene expressed in Saccharomyces 
cerevisiae (99).  This led to the expression of a truncated but fully functional version of 
CYP3A4 and many other P450s in Escherichia coli (100). 
Some of the greatest hindrances to the biophysical characterization of 
recombinantly expressed CYP3A4 arise from the variability in reconstitution conditions.  
Imaoka and colleagues first showed that catalytic rates of testosterone hydroxylation 
change as a function of phospholipid constituents (101).  This was further complicated 
by the work of several laboratories, including Guengerich, Estabrook, and Halpert, 
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which showed drastically different catalytic rates depending on several variables:  the 
buffer used (HEPES, KPi, Tris-HCl), the salts (divalent metal ions) and phospholipids 
added (phosphatidylcholine versus phosphatidylserine), the saturation of the 
phospholipids (saturated, single unsaturated, or double unsaturated), the detergents 
used (CHAPS, cholate, Emulgen 911 or 913), the presence or absence of auxiliary 
proteins (cytochrome b5) and the order in which the reconstitution components are 
added (102-116).  This is still a problem with the biophysical characterization of 
CYP3A4 as there is no standardized optimal set of conditions under which this enzyme 
is usually studied.   
 CYP3A4’s in vitro parameters have widely been examined including many 
detailed studies of individual reaction steps in the catalytic cycle (70, 117-120) and 
shown to be complex (118, 121-123).  It demonstrates both heterotropic and homotropic 
cooperativity, which can manifest as both positive and negative cooperativity (78).  
Differing metabolic profiles have been shown with varying substrate pairs, such as 
testosterone or progesterone in the presence of α-naphthoflavone (124).  The 
testosterone and progesterone change the metabolic profile, altering the ratio of the 
main metabolite to minor metabolites when α-naphthoflavone is added to the reaction 
mixture.  This is thought to be due to the differential binding of multiple substrates in one 
large active site and a different presentation of the substrate to the reactive oxygen 
intermediate (124).  Studies of active site accommodation by several methods, including 
X-ray crystal structures (125-126), NMR relaxation (127-128), eximer fluorescence 
(129), and the simultaneous analysis of multiple data sets (130-131) show that the 
CYP3A4 active site can accommodate at least two, and possibly three, substrates at 
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any given time.  However, the use of non-homogeneous systems may lead to some of 
these complex behaviors.   Multiple sources claim there are several nonequivalent 
populations of CYP3A4 in a reconstituted system (121, 132-133). 
 
1.6 Methods for the Characterization of Membrane Associated Proteins 
 Appropriate experimental methods are necessary in the biophysical and 
biochemical studies of a membrane associated enzyme, especially to ease the 
spectroscopic analysis of measured thermodynamic and catalytic parameters, and 
prevent aggregation.  In order to increase the signal to noise ratio, the sample is 
rendered soluble for study.  Options include membrane preparations, detergent 
solubilization liposomal systems, and Nanodiscs (134-136).  Each of these methods has 
its own advantages and drawbacks and have helped to elucidate the behavior of 
CYP3A4. 
 A whole cell membrane suspension may be used when first trying to 
biophysically characterize a target protein.  This furnishes a phospholipid bilayer with 
unknown lipid constituents to aid in the stabilization of the enzyme under study.  Studies 
performed on whole cell membrane suspensions yield knowledge about the reactions 
that can be catalyzed by the enzyme of interest and limit the use of detergents, which 
may disrupt the molecular recognition events that are critical for proper enzyme 
function.  The membrane suspensions are of particular use if it is not necessary to 
examine the fully purified protein.  This methodology can lead to cross-reactivity of the 
measured catalytic reaction, making this type of measurement possibly unreliable, as 
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another enzyme or cross-reactivity may be present.  Many studies of CYP3A4 
performed using liver microsomes have led to novel insights into the catalytic 
mechanism of CYP3A4 (90, 137).  The downside to this type of investigation lies in the 
presence of multiple cytochrome P450 isoforms in these tissue samples (48, 138-139).  
Another complicating factor is the size of these microsomes, as well as the 
complications for spectroscopic analysis that are associated with light scattering. 
 Detergent solubilization systems have been very useful in the biophysical 
characterization of cytochromes P450.  Detergents that have been commonly used to 
study CYP3A4 include CHAPS, Emulgen 911 and 913, Triton X-100, and cholate.  
When using detergents in the solubilization of cytochromes P450, care must be taken to 
ensure that the detergent used does not change the activity of the enzyme.  It has been 
shown that several of the detergents commonly used in the study of substrate binding 
and catabolic reactions are themselves substrates of CYP3A4 (140).  In spite of these 
drawbacks, the use of detergents as a solubilization system has several advantages, 
such as the ease of enzyme preparation and the ability to study a purified sample that 
has decreased light scattering due to the smaller particle size.  However, the actual size 
of the particles is usually in question, as the detergents form unknown micellar 
structures around the target enzyme, so the actual enzyme structure may not be the 
same as in a natural phospholipid bilayer.  This can lead to complications in the 
understanding of the chemical mechanism or biophysical characterization of membrane 
associated proteins (78, 102, 108, 141).  There are also concerns that there may be 
unknown oligomeric structures of enzymes that may play a role in conformational 
heterogeneity (132-133).   
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 Unilamellar vesicle systems has been of great use in the study of cytochromes 
P450, for they have been shown to greatly enhance the metabolic rates of P450s when 
complexed with their redox partner (141).  Unilamellar vesicles consist of a single 
phospholipid bilayer into which the enzyme is incorporated through vesicle extrusion, 
sonication, or detergent dialysis (141-142).  Large unilamellar vesicles (LUVs) are 100 
nm or more in diameter, and are produced by vesicle extrusion or detergent dialysis, 
while sonication produces small unilamellar vesicles (SUVs), which are 25 - 50 nm in 
diameter.  The difficulty with these systems arises when attempting to understand the 
higher-order structures of the enzyme components, or when there is any domain 
formation or domain capping of these enzymes in the unilamellar vesicles.  Due to their 
size, the vesicle systems usually give rise to light scattering events that can obstruct the 
measured spectroscopic parameters.  A further complication that arises when 
incorporating a protein into vesicle systems is the statistical chance that the enzyme 
may be incorporated into the lumenal side of the vesicle, thus obstructing it from bulk 
solvent and interaction with an analyte molecule.  This may also change the measured 
parameters of the enzyme, because the expected substrate concentration or analyte 
that is presented to the enzyme in the lumen may be different then in bulk solvent.    
 Nanoscale phospholipid bilayer systems, named “Nanodiscs,” have been in 
development since 1998 (143-144).  These particles were invented from an interesting 
observation, namely that there is a transient structure of the HDL that forms small 
discrete discoidal phospholipid bilayers.  The HDL functions in vivo to transport lipid and 
cholesterol around the body by complexing an amphipathic, mostly alpha helical protein 
Apo A1, with phospholipids and cholesterol (143, 145-148).  At a specific protein to lipid 
18 
 
ratio, the ApoA1 forms discoidal phospholipid bilayers.   A gene was designed to 
enhance the expression of this protein in E. coli, to remove any mRNA secondary 
structure, remove the LCAT signaling and molecular recognition domains, and to 
optimize the production of this protein via optimal codon usage (149).  This new 
genetically engineered amphipathic alpha helical protein was termed Membrane 
Scaffold Protein, MSP.  Since its inception and initial publication, there have been 50 or 
so variants made, changing the Nanodisc size and the amino acid sequence for 
chemical modification, and multiple cleavage sequences and affinity tags have been 
incorporated for different applications (149-153).  These Nanodiscs are a soluble, 
monodisperse phospholipid bilayer of a discrete size ranging from 9.7 nm to 17 nm in 
diameter (153-154).  This system has allowed for incorporation of monomeric CYP3A4 
for a variety of biophysical studies including cryo-spectroscopy, stopped-flow, and solid 
state NMR (134, 155-157). 
 
1.7 Cooperative Behavior of Cytochromes P450 
Many cytochromes P450, such as CYP3A4, have large flexible substrate binding 
pockets capable of accommodating relatively large substrates, >1000 Da, or two or 
three smaller organic substrates.  Binding of multiple substrates and their interactions 
gives rise to deviations from the simple hyperbolic dependence of functional enzyme 
properties on the concentration of substrate.  This is often referred to as homotropic 
cooperativity in the case of multiple molecules of the same substrate, or heterotropic 
cooperativity in the case of different substrates.  Cooperativity is typically defined as the 
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interaction between the binding sites on a macromolecule (158).  Positive cooperativity 
is present if the binding of a substrate to one site increases the affinity of other binding 
sites, and it is negative in the opposite case.  If the site is not involved in catalytic action, 
this effect is often termed allosteric.  Upon binding an allosteric effector molecule, the 
catalytic activity of the enzyme towards the substrate may be enhanced, in which case 
the effector is an activator, or reduced, in the case of an inhibitor. 
Sigmoidal kinetics of 6β-hydroxylation of androstenedione by purified 
cytochromes P450 was observed over 30 years ago for rabbit P450 isozymes 
reconstituted in phospholipid vesicles (159).  Heterotropic effects of ANF and 
progesterone on the activity of rabbit P450 isozymes were described shortly later (160-
161).  Cooperativity has been reported in numerous systems, in vivo (162), in liver 
microsomes (163-166), and in purified enzyme reconstituted systems (78, 167-169).  In 
addition to CYP3A4, several isozymes have been reported to show cooperative 
behavior.  It has been well documented with CYP107 (170-171), CYP2C9 (172-174), 
and others include the xenobiotic metabolizing enzymes CYP1A2 (175), CYP2A6 (176), 
CYP2B1 (177), CYP2B6, and CYP2E1 (178), bacterial enzymes CYP102 (179), 
CYP130 (180), CYP158A2 (181), P450 crpE (182), and even chloroperoxidase (183-
184). 
1.7.1 Cooperativity of Cytochrome P450 3A4 
Positive cooperativity has been observed in CYP3A4 binding experiments where 
heme iron spin shift was monitored by changes in the optical absorption using several 
substrates including testosterone (TST) (116, 118, 127, 155, 185-187), progesterone 
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(116), pyrene butanol (131, 188), 7-benzyloxy-4-(trifluoromethyl)coumarin (188), ANF 
(187, 189-190), 7-benzyloxyquinoline (191), flavone (118), and Nile Red (192).  These 
sigmoidal spin shift curves generally fit with low Hill coefficients (n < 2.0), consistent with 
two or three substrate molecules binding simultaneously.  However, other substrates 
and inhibitors such as bromocriptine (118), erythromycin (185), ketoconazole, 
midazolam (118), and acetaminophen (128) bind with no apparent cooperativity.  The 
list of substrates for which sigmoidal kinetics has been observed in microsomes 
includes aflatoxin B1, amitriptyline, carbamazepine, diazepam, estradiol, nifedipine, 
progesterone, and testosterone (193). 
The first systematic study of heterotropic effects in CYP3A4 showed that 
phenanthrene metabolism was activated by ANF and that both of these compounds 
were substrates for the enzyme (137), indicating both could access the active site since 
neither could competitively inhibit the other substrate.  Heterotropic interactions were 
recently compiled in a comprehensive list by Niwa et al. (163).  ANF is one of the most 
commonly studied effectors (although it is also a substrate as previously noted), and 
exhibits seemingly contradictory effects on CYP3A4 metabolism.  It has been shown to 
activate a number of reactions including TST hydroxylation, aflatoxin B1 epoxidation, 
17β–estradiol hydroxylation, while also inhibiting aflatoxin B1 hydroxylation (194).  It 
also activates progesterone hydroxylation (189), diazepam hydroxylation and 
demethylation (195), carbamazepine expoxidation (196), and nifedipine oxidation (197).  
ANF simultaneously activates carboxylic acid formation and inhibits hydroxylation of 
losartan, while losartan inhibits ANF epoxidation (198).  Interestingly, ANF stimulates 
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midazolam 1’-hydroxylation and inhibits 4-hydroxylation, TST has the opposite effect on 
the two midazolam products (199). 
Several models have been proposed to account for these cooperative 
observations including a single large binding pocket which can accommodate different 
combinations of substrates and/or effectors, a model with distinct allosteric peripheral 
binding sites that exert influence through conformational changes in the enzyme, and a 
model with distinct populations of enzyme in various oligomeric states (121, 200-201). 
1.7.2 Modeling Cooperative Ligand Binding 
 Understanding drug clearance in vivo based on in vitro studies requires applying 
the in vitro derived parameters as a basis for intrinsic clearance (202-203): 
Rate of metabolism = CLint • [S] = (Vmax • [S]) / (Km + [S]) 
Where CLint is the intrinsic clearance, [S] is the drug concentration, Vmax is the maximal 
velocity and Km is the concentration at which half-maximal velocity is observed.  This 
assumes the drug’s metabolism follows Michaelis-Menten type kinetics. 
If Km >> [S] then: 
CLint =  (Vmax • [S]) / Km 
By substituting back into the prior equation: 
 CLint = Vmax / Km  
and: 
22 
 
 CLint = Rate of metabolism / [S] 
This relation allows one to use Michaelis-Menten parameters to estimate in vitro 
clearance (204).  However, cooperative interactions typically involve more complex non-
Michaelis type kinetics, and utilizing the Michaelis-Menten parameters, such as Km and 
Vmax, to model these observed phenomena will cause misleading conclusions regarding 
the drug clearance.  It is necessary to develop better models of cooperative interactions 
to more accurately predict drug clearance from in vitro data. 
Definitions of cooperativity are, in general, based either on the purely 
phenomenological approach to the analysis of experimental data, or on an a priori 
model of two or more identical binding sites with interactions between them.  The first 
approach relies on the non-Michaelis (or non-Langmuir) shape of the plot of the enzyme 
property as a function of the substrate concentration (205).  The simple hyperbolic 
binding isotherm is characteristic for the ensemble of macromolecules each having one 
or several identical binding sites with dissociation constant K.  For one binding site on 
each macromolecule, the binding scheme consists of only one step:   
 
The equation for the binding isotherm is a hyperbolic Langmuir isotherm:  
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For two binding sites, which are not identical, there are four site-specific 
(microscopic) equilibrium dissociation constants, k11, k21, k12, k22, three of which are 
independent, because the relation k11•k12 = k21•k22 always holds in equilibrium due to 
thermodynamic energy conservation. 
 
The corresponding stoichiometric (macroscopic) dissociation constants K1 and K2 
can be expressed as K1= (k11+k21), K2 = k11•k12/(k11+k21).  Concentrations of the binding 
intermediates [E0], [ES1], and [ES2], and the relative populations of the enzyme with 
zero, one, and two substrate molecule bound, y0, y1, and y2, can be calculated from the 
stoichiometric equilibrium: 
[ES1] = [E0] • [S] / K1 
[ES2] = [ES1] • [S] /K2 = [E0] • [S]2 / K1 • K2,  
[Etotal] = [E0] + [ES1] + [ES2] = [E0] (1 + [S] / K1 + [S]2 / K1 • K2) 
The overall binding isotherm is expressed as the following equation:  
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Here y1 and y2 are fractions of the binding intermediates [ES1] and [ES2], i.e. the relative 
populations of the enzyme with one or two ligand molecules bound, and Y is the fraction 
of binding sites occupied by ligands. 
For identical non-interacting binding sites (no cooperativity), k11 = k21 = k12 = k22 = 
k, the shape of binding isotherm is the same as for the single site model, with k as a 
binding constant, but the stepwise (stoichiometric) binding constants become:  
 K1= 2k,  
 K2 = k/2 = K1/4. 
If the two sites are distinct and independent: 
 k11 = k22 = k1 
 k21 = k12 = k2 
and 
 K1= (k1+k2) 
 K2 = k1•k2/(k1+k2)  
Using these relations, it is easy to show that K2 < K1/4, if k1 ≠ k2. Therefore, for two-site 
binding with intrinsically different sites, the binding isotherm is indistinguishable from the 
presence of negative cooperativity in the system with identical sites.  
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In the presence of a positive cooperative interaction between sites, the second 
binding step occurs with higher affinity than it would have had the first site been 
unoccupied, meaning that k12 > k21, and k22 > k11. For the two-site system one can 
define a cooperativity coefficient α = k12/k21 = k22/k11, where α > 1 corresponds to 
positive cooperativity, and α < 1 to negative cooperativity. Then the site-specific binding 
constants are: 
 k11 = k1, k22 = α•k1, 
 k21 = k2, k12 = α•k2, 
The stoichiometric binding constants:  
 K1= (k1+k2) 
 K2 = α•k1•k2/(k1+k2)  
Note that the same cooperativity coefficient α appears as the measure of 
cooperativity for the stoichiometric stepwise binding constants K1 and K2, and for the 
microscopic site-specific binding constants kij.  If the site-specific microscopic binding 
constants differ by factor p, so that k1=pk2, then K1=(p+1)k2 and K2=k2 αp/(p+1), there is 
a positive cooperative interaction between these sites with α=(p+1)2/4p. Then K2=K1/4 
and the binding isotherm will be hyperbolic, with no apparent cooperativity. Thus, for the 
system with intrinsically different sites, the presence of site-specific cooperativity has to 
be evaluated through additional independent measurements of site-specific binding 
constants.  Only overall apparent cooperative or non-cooperative behavior of the 
system is indicated by the shape of binding isotherm. 
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These equations help one to understand and evaluate cooperativity in terms of 
experimentally derived quantities (the equilibrium binding constants) which can be 
measured directly using various methods (206-207).  Typically, the stepwise 
stoichiometric binding constants Ki can be derived from experimental data in more 
straightforward manner than microscopic site-specific constants kij.  The stoichiometric 
binding scheme, or sequential binding model, does not rely on any specific model 
assumptions about the nature and mutual influence of binding sites, but rather assumes 
an overall binding stoichiometry.  For the systems with more than two binding sites the 
complete resolution of all site-specific constants from analysis of the binding isotherm is, 
in general, impossible because of the number of independent parameters to fit: seven 
for three sites, fifteen for four sites; for further analysis see (208-209). 
For three binding sites, the binding isotherm can also be expressed through 
stoichiometric binding constants:  
 
 
The multipliers 1/3, 2/3, and 3/3 at the right side of the equation yield the 
fractional contributions to the binding isotherm from each binding intermediates, 
corresponding to the fraction of binding sites occupied by ligand.  However, if the 
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measured signal is not directly proportional to the fraction of occupied binding sites, this 
equation will look different:  
 
This form provides a useful representation of binding isotherm as a sum of contributions 
of binding intermediates and will be used further in analysis of functional cooperativity 
operating in the cytochromes P450, in chapter four. 
If the number of binding sites and binding stoichiometry is unknown, the Hill 
equation is commonly used to characterize the binding cooperativity with one averaged 
parameter, the Hill coefficient.  Originally, this equation was derived to describe the 
cooperative binding of oxygen and carbon monoxide to hemoglobin, assuming that the 
protein is composed of several subunits, which bind ligands simultaneously (210-212), 
or with infinite cooperativity:  
 
The binding isotherm for this binding scheme is described by the Hill equation:  
 
K is the dissociation constant for binding of one ligand, so that the Nth order reaction of 
simultaneous binding of n ligands is defined by the Nth power of K.  By definition, Hill 
coefficient nH represents the number of subunits acting simultaneously which is 
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unrealistic.  However, fitting of experimental data with the Hill equation is widely used as 
a simplest two-parameter approximation without additional knowledge of the binding 
stoichiometry.  The position of the midpoint of the binding isotherm S50 = K 
characterizes averaged affinity, and the Hill coefficient nH, being a quantitative measure 
of apparent cooperativity, defines the sigmoid shape of binding isotherm.  Physically, 
the interpretation of the Hill coefficient is equivalent to the average size of cooperative 
domain in the studies of thermotropic phase transitions in lipid bilayers, which is 
calculated as a ratio of van’t Hoff and calorimetric enthalpies (213), or the similar mean 
size of cooperative unit for the helix-coil transition point in the Zimm-Bragg model 
calculated as an average length of the helical segment undergoing conformational 
transition (214-215).  All these representations provide a useful quantitative measure of 
cooperativity by comparison of the real experimental system to the simple model of the 
small but infinitely cooperative system, which has the same shape of the transition 
curve.  However, the Hill coefficient is not equal to the number of binding sites or 
subunits of the real macromolecule.  It indicates only the minimal number of binding 
sites, which cannot be lower than nH.  The value of S50 is also not a binding constant by 
itself, but a composite of the real binding constants (216).  
Bardsley and Wyman (217) provided a useful, general analysis of the shape of 
binding isotherm as an indicator of cooperative interactions in the system.  It shows that, 
in general, the sign of Hessian of the binding polynomial at the given substrate 
concentration defines the curvature of the binding isotherm and thus the presence and 
sign of cooperativity at the given point.  In the case of more than two binding sites, the 
sign of cooperativity may be different as the interactions between binding sites can be 
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favorable or unfavorable (158, 218-220).  The unambiguous conclusion of the presence 
of cooperativity in the system based solely on the shape of binding isotherm can be 
reached only in case of positive cooperativity, while the presence of apparent negative 
cooperativity may be due to the heterogeneity of the binding sites.  The application and 
validity of the Hill plot and equation to the analysis of cooperative binding to dimers and 
tetramers have been analyzed by Cornish-Bowden and Koshland (221) and Bardsley 
(222) for heterogeneous three-site binding.   
Another approach to define cooperativity is based on the explicit theoretical 
model of several binding sites on the macromolecule.  Detailed analysis can be found in 
several excellent books (219-220, 223).  If these multiple sites are independent and 
binding of the ligand at any one does not depend on the occupation of other, the system 
is non-cooperative.  However, if the affinity of the site changes as a result of the 
presence of ligands at another site, then there is a cooperative interaction between 
them, often called site-specific cooperativity (158).  This definition requires knowledge of 
the binding stoichiometry, and the separate measurement of the site-specific binding 
constants which are unperturbed by their cooperative interactions.  The measurement of 
these constants can be achieved using site-specific mutations (224-225), but such 
experiments rely on the detailed structural information which is unavailable in most 
cases.  
In the case of different functional response from two binding sites, for example 
different spin shift caused by the first and the second ligand binding, the substrate 
concentration dependence of this property  may appear cooperative even without 
binding cooperativity.  If the first binding is “functionally silent” the second provides most 
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of the signal and generates an apparently cooperative response. This is the most 
relevant case with respect to the several mammalian cytochromes P450, including 
human CYP3A4 (130), human CYP2C9 (226), rabbit CYP1A2 (175), and several 
others, like CYP107 (171, 227), in which the catalytically competent enzyme-substrate 
complex was only formed upon the second, lower affinity binding event.  
1.7.3 Heterotropic Cooperativity 
Heterotropic cooperativity, when ligands of two different types can interact 
simultaneously with one enzyme, has been reported for several cytochromes P450 
including CYP3A4, CYP3A5, and CYP2D6, (163), CYP2C9 (228), CYP1A2 (229), 
CYP107(230), and CYP102 (231).  The ability of one ligand (effector) to enhance the 
metabolism of another (substrate) is often called positive heterotropic cooperativity, 
even if there is no information on the enhancement of binding of the substrate in the 
presence of the effector.  Heterotropic effectors may be substrates themselves and can 
seemingly abolish homotropic cooperativity of the other substrate, as is the case for 
ANF and its effect on TST hydroxylation (194) and progesterone hydroxylation (116) in 
CYP3A4.  Heterotropic cooperativity is typically treated as positive cooperativity, since 
observed inhibition is commonly explained by competitive, noncompetitive or 
uncompetitive models (162-163). 
 Korzekwa et al. (201) developed a complete and simplified kinetic schemes for a 
binding model with either two catalytic sites, or one catalytic and one effector site.  
Others have developed similar schemes (198, 232).  This model involves six different 
binding intermediates and three catalytic rate constants and is too complex to analyze 
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for the behavior of two catalytic sites.  Using the rapid equilibrium assumption (233) it is 
possible to simplify the model and derive an equation for positive heterotropic 
cooperativity in the model with one effector and one catalytic site: 
 
 
Here Km is the apparent Michaelis constant from the ES binding intermediate, and α and 
β represent cooperativity coefficients induced by the effector, B.  This analysis, like 
others which include the simultaneous binding of two substrates and one effector, 
allows for the estimation of kinetic and cooperative parameters for the substrate, but 
only a binding constant for the effector (167).  In the case where both interacting 
molecules are enzymatic substrates, these methods do not take into account the full 
extent of the landscape of heterotropic interactions, instead dividing the two substrates 
into two substrate-effector pairs for individual analysis. 
 Other more complex models have been developed for cases where three 
substrates are in the active site simultaneously, or where the effector activates at lower 
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concentrations and inhibits at higher concentrations (234-236).  However, because of 
the number of parameters involved in these models a large number of data points must 
be collected in order to accurately describe the system (216). 
In order to expand upon the understanding of heterotropic interactions in 
cytochromes P450 and their potential role in deleterious drug-drug interactions, this 
work describes the development of a model for a complete description of the 
heterotropic interactions of the ANF and TST substrate pair, using a homogenous 
monodisperse population of CYP3A4 embedded into Nanodiscs.  By monitoring multiple 
observable properties and simultaneously fitting the data sets to the model the 
individual state properties of the various enzyme-substrate complexes, along with the 
step wise binding constants are deconvoluted for the individual substrates and the 
mixed substrate system.  By varying the ratio of the two substrates and comparing the 
observed kinetic data to a corresponding linear combination of the two substrates’ 
individual kinetic profiles, which represents the absence of heterotropic interactions, 
conclusions about the presence or absence of heterotropic cooperativity can be made 
using a limited number of parameters. 
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CHAPTER TWO:  HETEROTROPIC COOPERATIVITY OF HEME IRON SPIN STATE 
IN CYTOCHROME P450 3A4 NANODISCS PROBED WITH TESTOSTERONE AND 
α-NAPHTHOFLAVONE 
 
2.1 Introduction 
Both testosterone (TST) and α-naphthoflavone (ANF) (figure 2.1) bind to 
CYP3A4 inducing a Type I spin conversion by displacing water as the axial heme 
ligand, and cause a shift from the low spin ferric state to the high spin ferric state 
observable by a change in the position of Soret band in UV-vis absorbance spectra from 
416 nm to 393 nm.  The correlation between  the spin state and the ligation state of the 
heme iron and the redox potential has been established for soluble P450s (237-239), 
and recent work has shown that this also holds true for monomeric CYP3A4 embedded 
Nanodiscs (240), implicating the spin state (and ligation state of the heme iron) as an 
universal regulator of metabolic control.  Titrations of either substrate monitored by UV-
vis spectroscopy deviate from a standard Langmuir curve suggesting that multiple 
binding events occur and that these events are apparently cooperative.  Previously 
reported parameters from fitting these titrations to the Hill equation yield ranges of, S50 = 
28 – 58 µM, n = 1.3 – 2.2 (116, 118, 130, 155) for TST, and, S50 = 3.7 – 50 µM, n = 1.2 
– 2.2 (118, 185, 187, 189, 241) for ANF.  However, it should be noted that the 
experiments reported by Roberts et al. (241) were performed at a concentration of 5 µM 
CYP3A4, and resulted in significant difference from the other experiments reported.  
The variation in these numbers is likely due to the variety of systems (liposomes, 
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Nanodiscs, or detergent solubilized), and conditions such as temperature (ambient, 25° 
C, or 37° C), and CYP3A4 concentration (0.5 – 5 µM) which may affect the enzyme 
oligomerization state. 
 
Figure 2.1 Substrates and Major Metabolite Products. 
In order to avoid the effects of CYP3A4 oligomerization, and to elucidate the 
mechanism of heterotropic cooperativity of monomeric CYP3A4, the enzyme was 
solubilized in Nanodiscs (130, 155-156). Nanodiscs are ~10 nm diameter phospholipid 
bilayer membrane patches stabilized by MSP, which allow for the incorporation of a 
single membrane protein into native like environment.  This creates a homogenous, 
monodisperse, and stable protein sample suitable for the study of many integral 
membrane proteins (190, 242).  Homotropic spectral titrations of TST to CYP3A4 in 
Nanodiscs was studied in detail previously (155), along with a rigorous characterization 
of the incorporation of the enzyme into the Nanodisc lipid bilayer by size exclusion 
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chromatography (SEC) and small angle x-ray scattering (SAXS).  In this study the high 
Hill coefficient (n > 2.2) is indicative of at least three TST binding events, with the first 
event only contributing a minor portion of the high spin signal.  Similarly, multiple 
molecules of ANF can bind to CYP3A4, and the first binding event also appears to be 
silent with respect to the spin shift (118, 187, 190, 241). 
ANF is one of the most widely studied effectors of CYP3A4 and it has been 
shown to stimulate a number of CYP3A4’s catalytic reactions (160, 194-195, 197-199, 
243) as well as eliminate the positive homotropic cooperativity typically observed for 
binding and/or metabolism of TST and progesterone (116, 194).  However, the origin of 
these effects remains unclear and seemingly contradictory in the literature, since it is 
studied in concert with a variety of other CYP3A4 substrates, and is sometimes treated 
solely as an effector while other times as an independent substrate.  In some cases 
ANF is reported to act as an inhibitor for CYP3A catalyzed reactions, including the 6β-
hydroxylation of testosterone by CYP3A4 (194) and CYP3A6 (244), but sometimes as 
an activator (160, 195, 197, 199).  ANF is itself a substrate for CYP3A4 (198, 245), and 
as such may serve as a competitive inhibitor.  However, it is also one of the most well 
documented effectors for CYP3A4 heterotropic cooperativity, particularly in combination 
with TST (21, 121-122, 163, 246). Results of a recent study (241) suggested a 
moderate positive cooperative interaction between ANF and TST, as estimated by the 
spin shift of CYP3A4. 
Type I spin state changes of CYP3A4 have been measured as a function of ANF 
and TST concentrations as individual substrates, and compared to the Type I spectral 
changes induced in mixed titration experiments with fixed molar ratios of the two 
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ligands.  This method of deconvolution of the additive and heterotropic cooperative 
effects allows for analysis of changes in the spectral dissociation constant, S50, as the 
concentrations of both substrates were simultaneously altered, revealing changes in the 
enzyme’s overall spectral transition for both substrates as a function of their molar ratio.  
In the absence of specific heterotropic cooperativity the overall affinity of a given 
substrate ratio in the system for the enzyme is represented by a linear combination of 
the affinities of the two individual substrates while deviations from this behavior 
represent additional positive or negative cooperative interactions which give rise to the 
non-additive effects (247-248).  Analysis of the mixed titrations at different molar ratios 
of the substrates, as compared to the single substrate titrations, showed that the 
stimulatory effect observed in the presence of the second substrate was entirely due to 
its additive effect and revealed the absence of any specific heterotropic cooperative 
interactions between ANF and TST in the monomeric CYP3A4. 
 
2.2 Materials and Methods 
2.2.1 Expression and Purification of CYP3A4 
The clone of CYP3A4his NF-14 in pCW Ori+ was graciously provided by F. P. 
Guengerich (Vanderbilt University Nashville, TN).  The heterologous expression of 
CYP3A4his in E. coli has been described (185) and the growth and purification 
procedure has been modified to improve both the expression yield and ease of 
purification (156).  The CYP3A4his has an N-terminal truncation of 10 amino acids at 
positions 3-12 and a single point mutation S18F to create the construct CYP3A4his NF-
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14 pCW Ori+ which helps in the expression of this protein in E. coli and aids in the 
formation of the holo enzyme over either the apo or the P420 form.  The CYP3A4his 
has a pentahistidine affinity tag engineered at the C-terminus.  The expression of 
CYP3A4his was accomplished by first transforming the clone into E. coli DH5α f’ Max IQ 
supercompetent cells using the manufacturer’s protocol.  The transformed E. coli were 
plated on LB agar plates containing 50 µg/ml ampicillin and incubated at 37° C 
overnight.  A single colony was added to 10 ml of LB media containing 100 µg/ml 
ampicillin and shaken at 220 RPM at 37°C, and grown overnight.  This was used as the 
starter culture for growth in TB enhanced with BactoPeptone (2 g /L) and 250 µL trace 
minerals  (100 mM FeCl3●6 H2O, 10 mM ZnCl2●4 H2O, 10 mM CaCL2●6 H2O, 8.0 mM 
Na2MoO4, 7.5 mM CuCl2, 8.0 mM H3BO3, and 1.0 mM thiamine).  The media was 
inoculated with 10 ml of starter culture and grown at 37˚C with shaking at 200 RPM until 
OD600 was 0.8.  The cells were then induced with a final concentration of 1 mM IPTG, 4 
g of L-arabinose and 1 mM δ-Aminolevulinic acid to help promote holoenzyme 
formation.  This induced cell culture was grown for an additional 48 hours at 30° C with 
shaking at 200 RPM.  The cells were harvested using a J2-21 Beckman-Coulter 
centrifuge with a JA-10 rotor.  They were isolated from the growth media by spinning at 
8000 x G for 10 minutes and stored at -80° C until the purification was performed.   
The cells were resuspended in 50 mM potassium phosphate buffer pH = 7.4, 0.5 
M sodium acetate, 20% glycerol, 5 mM beta-mercaptoethanol, 1 mM PMSF.  1% 
CHAPS was added and then the cell suspension was sonicated using a Branson 
Sonifier 450 set to a duty cycle of 80% and an output of 7 for 1 minute and then allowed 
to rest on ice for three minutes, for four cycles.  The cells were centrifuged using a 
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Beckman-Coulter L8-55m preparative ultracentrifuge with a Ti-45 rotor for 30 min at 
30,000 RPM to clarify the lysate.  The lysate was loaded onto a 25 ml Hi-Trap Metal 
Chelating resin, charged with 0.1 M nickel sulfate and equilibrated with 50 mM 
potassium phosphate buffer pH = 7.4, 0.25 M sodium acetate, 20% glycerol, 1% 
CHAPS, followed by ten column volumes of:  the equilibration buffer, the buffer 
supplemented with 15 mM imidazole; the buffer supplemented with 15 mM imidazole, 
0.1% Emulgen 913 and without CHAPS; and eluted with 50 mM potassium phosphate 
buffer pH = 7.4, 0.25 M sodium acetate, 20% glycerol, 0.1% Emulgen 913, 0.3 M 
imidazole.  The fractions were pooled and dialyzed three times against 1000 x volume 
of 50 mM potassium phosphate pH = 7.4, 20% glycerol (v/v).  The dialyzed samples 
were then aliquoted and flash frozen in liquid nitrogen and stored at -80° C until use.  
Purified CYP3A4 was quantitated using carbonmonoxy bound ferrous difference spectra 
using an extinction coefficient of 91 mM-1 cm-1 (3). 
2.2.2 Expression and Purification of Membrane Scaffold Protein MSP1D1 
The Membrane Scaffold Protein 1D1 (MSP1D1) expression and purification has 
been previously described (149, 153) synthetic gene was cloned into a pET 28 vector 
and transformed and expressed in BL21 (DE3) Gold E. coli.  The transformed E. coli 
were plated on an LB agar plate containing 30 µg/ml kanamycin and incubated 
overnight at 37˚C.  A single colony was selected and added to a 5 ml LB culture 
supplemented with kanamycin, and was incubated at 37˚C with shaking at 220 RPM 
until the culture reached an OD600 of 1.5.  1 ml of the culture was added to 50 ml of 
culture media and incubated at 37˚C with shaking at 220 RPM until the OD600 was 3.0.  
The culture was added to a Bio-Flow III fermentor containing 2.5 L of TB, and growth at 
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37˚C with agitation of 500 RPM and air flow of 3.0 L/min was monitored until the OD600 
reached 2.5 at which point target protein synthesis was induced by addition of IPTG to a 
final concentration of 1 mM, and growth was continued for an additional hour at 37 ˚C, 
and then four more hours at 28˚C.  The cells were harvested in a Beckman J2-21 
centrifuge using a JA-10 rotor at 8000 x G for 10 minutes.  The cell pellet was stored at 
-80˚C until purification. 
The cells were resuspended in 15 mM potassium phosphate pH = 7.4, 50 mM 
NaCl buffer with a final concentration of 1.0% Trition X-100 (w/v).  They were incubated 
for 30 minutes on ice and sonicated with a Branson Sonifier 450 set to a duty cycle of 
60% and output of 7, for 30 seconds followed by a 90 second rest six times.  The cell 
suspension was spun at 25,000 x G in a Beckman Ti-45 rotor for 30 minutes, and 
purified over a Hi-Trap Metal Chelating resin 2.5 x 5 cm column, charged with 0.1 M 
nickel sulfate and equilibrated with three column volumes of the resuspension buffer, 
washing with three column volumes of the following buffers: 40 mM Tris-HCl pH 8.0 0.3 
M NaCl 0.1% Triton X-100, 40 mM Tris-HCl pH 8.0 300 mM NaCl 50 mM cholate, 40 
mM Tris-HCl pH 8.0 0.3 M NaCl, 40 mM Tris-HCl pH 8.0 0.3 M NaCl 50 mM imidazole.  
The protein was eluted with 40 mM Tris-HCl pH 8.0 0.3 M NaCl 250 mM imidazole. 
2.2.3 Expression and Purification of TEV Protease 
TEV protease expression and purification followed a previously described 
procedure (249).  The transformed E. coli were plated on an LB agar plate containing 
100 µg/ml ampicillin 30 µg/ml chloramphenicol and incubated overnight at 37˚C.  A 
single colony was selected and added to a 50 ml LB culture supplemented with 
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ampicillin and chloramphenicol, and was incubated at 37 ˚C with shaking at 220 RPM 
until the culture reached an OD600 of 0.8.  10 ml of the culture was added to 1 L of 
culture media and incubated at 37˚C with shaking at 220 RPM until the OD600 was 0.8 at 
which point target protein synthesis was induced by addition of IPTG to a final 
concentration of 1 mM, and growth was continued for four additional hours at 30˚C.  The 
cells were harvested in a Beckman J2-21 centrifuge using a JA-10 rotor at 8000 x G for 
10 minutes.  The cell pellet was stored at -80˚C until purification. 
The cell pellet was resuspended in 60 ml of lysis buffer, 50 mM Tris-HCl pH 8.0, 
10 mM BME, 0.1% Triton X-100, 5% glycerol, and sonicated with a Branson Sonifier 
450 set to a duty cycle of 60% and output of 7, for 30 seconds followed by a 90 second 
rest four times.  The cell suspension was spun at 30,000 x g in a Beckman Ti-45 rotor 
for 30 minutes, and purified over a 25 ml Hi-Trap Metal Chelating resin 2.5 x 5, charged 
with 0.1 M nickel sulfate and equilibrated with three column volumes of the lysis buffer, 
washed with 5 column volumes of lysis buffer plus 0.3 M NaCl, 50 mM imidazole, and 
eluted with lysis buffer plus 0.3 M NaCl, 0.5 M imidazole.  The elution was assayed by a 
colorimetric change using Coomassie Plus Protein Assay Reagent.  100 µL of assay 
reagent was added to 5 µL of protein solution in a 96 well microtiter plate, and the 
concentration was estimated by comparison to a BSA standard.  The fractions that 
contained protein were pooled and dialyzed twice overnight against 4 L 100 mM Tris-
HCl pH 7.5, 2 mM EDTA, 10 mM DTT, 0.2% Triton X-100, diluted 1:1 with 100% 
glycerol and stored at -80˚C until used. 
2.2.4 Cleavage of Histidine Tag from MSP1D1 
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MSP1D1 is genetically engineered to include a hexahistidine affinity tag that that 
can be cleaved using the TEV Protease from the Tobacco Etch Virus.  This protease 
site has a cleavage consensus sequence of Glu-X-X-Tyr-X-Gln/Ser.   Cleavage was 
carried out using a 1:100 TEV protease:MSP1D1 molar ratio in 50 mM Tris-HCl buffer 
pH = 8.0, 1.0 mM DTT, and 0.5 mM EDTA (153, 155).  This solution was incubated for 
12 hours at ambient temperature on an orbital shaker.  This was followed by dialysis 
against 4 L of 20 mM Tris-HCl pH = 7.4, 0.3 M NaCl, 50 mM imidazole three times to 
remove DTT.  The protein was loaded onto a 5 mL Hi-Trap Metal Chelating column, 
charged with 0.1 M nickel sulfate and equilibrated with the dialysis buffer.  The flow 
through was assayed by a colorimetric change using Coomassie Plus Protein Assay 
Reagent.  100 µL of assay reagent was added to 5 µL of protein solution in a 96 well 
microtiter plate.  The fractions that contained protein were pooled and dialyzed against 
4 L of 20 mM Tris-HCl pH = 7.4, 0.1 M NaCl, 0.5 mM EDTA three times, and checked 
by SDS page to determine cleavage efficiency.  The final concentration of cleaved 
MSP1D1 was calculated using the absorbance at 280 nm, and the corresponding 
extinction coefficient of 18.2 mM-1 cm-1 (153). 
2.2.5 Assembly of Plain Nanodiscs 
 Assembly of plain Nanodiscs was accomplished using the scaffold protein 
MSP1D1 after removal of its histidine tag by cleavage with TEV protease, following a 
modified procedure (149, 153).  A disc reconstitution mixture was prepared containing 
MSP1D1, POPC, and sodium cholate present in a 1:65:120 molar ratios.  Detergents 
were removed by treatment with Amberlite beads (1g/ml of disc reconstitution mixture), 
initiating a self-assembly process which forms discoidal POPC bilayer ~10 nm in 
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diameter stabilized by the encircling amphipathic MSP1D1 belt.  The discs were purified 
injected onto a Sephadex G-200 size exclusion column at a flow rate of 0.5 ml/min, 
equilibrated in 0.1 M HEPES buffer pH = 7.5, 15 mM MgCl2 , 0.1 mM DTT, to remove 
any partially formed discs or aggregated MSP1D1. 
2.2.6 Incorporation of CYP3A4 into Nanodiscs 
 
Figure 2.2 Schematic for Incorporation of CYP3A4 into Nanodiscs.  Adapted from 
Baas et al. 2004. 
Assembly of CYP3A4 in Nanodiscs (Figure 2.2) was accomplished using the 
scaffold protein MSP1D1 after removal of its histidine tag by cleavage with TEV 
protease, following a modified procedure (153, 155).  Purified CYP3A4 from the E. coli 
expression system was solubilized by 0.1% Emulgen 913 and mixed with a disc 
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reconstitution mixture containing MSP1D1, POPC, and sodium cholate present in 
1:10:650:1300 molar ratios respectively yielding an average final ratio of one CYP3A4 
per five Nanodiscs. Detergents were removed by treatment with Amberlite beads (1g/ml 
of disc reconstitution mixture), initiating a self-assembly process which incorporates 
monomer of CYP3A4 into a discoidal POPC bilayer ~10 nm in diameter stabilized by the 
encircling amphipathic MSP1D1 belt.  The discs were purified over a 5 mL Ni-NTA 
agarose column, equilibrated in 50 mM potassium phosphate buffer pH = 7.4, 0.3 M 
NaCl, washed with equilibration buffer plus 15 mM imidazole, and eluted with 
equilibration buffer plus 250 mM imidazole.  This removes any empty Nanodiscs, as the 
histidine tag resides on the P450.  Red fractions were pooled and concentrated and 
injected onto a Sephadex G-200 size exclusion column, at a flow rate of 0.5 ml/min, 
equilibrated in 0.1 M HEPES buffer pH = 7.5, 15 mM MgCl2 , 0.1 mM DTT, to remove 
aggregated CYP3A4.  Fractions were individually examined for bromocriptine binding, 
and those which did not show a ≥85% spin conversion at a saturating concentration 
were discarded.  The remaining pooled fractions showed a minimum 90% spin 
conversion. 
2.2.7 UV-Vis Spectroscopy 
Substrate binding was studied at 3 µM CYP3A4 in Nanodiscs using a Carey 300 
spectrophotometer. Absorption spectra have been measured at 37°C, in 100mM 
HEPES buffer pH 7.4, containing 7.5mM MgCl2 and 0.1mM DTT.  The substrates, TST 
and ANF, were added from stock solutions prepared at the desired molar ratio in 
methanol, with the final concentration of methanol never more than 1%. 
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2.2.8 Substrate Membrane Partitioning 
Partitioning of hydrophobic substrates ANF and TST into the lipid phase of 
Nanodiscs was taken into account by using the corresponding partition coefficients Kp = 
3000 and 500 respectively (190, 250). 
Considering all binding events as an equilibrium distribution of substrate between 
aqueous phase, lipid phase, and CYP3A4, the binding polynomial for the CYP3A4 in 
Nanodiscs will include an additional term to take into account partitioning of the ligand 
into bilayer. Two simultaneous equilibria are to be considered ((207), p. 118): 
[Sf]  [Sl]      and    [Sf]  [ES]. 
Here [Sf] and [Sl] are concentrations of the substrate in the aqueous phase and lipid 
phase, and [ES] is concentration of the enzyme-substrate complex. Because of 
partitioning of the substrate between aqueous phase and lipid bilayer, concentration of 
the free substrate in aqueous phase will be lower than that in the absence of 
partitioning, [Sf]0 by the constant factor determined by partition coefficient Kp and the 
volume fraction of the lipid phase, vl, vl  = Vl/(Vl+Vw), where Vl and Vw are the total 
volumes of the lipid and aqueous phases respectively (Figure 2.3).  If Vl << Vw, and 
(Vw+Vl)/ (Vw+ Kp • Vl)≈  1 / (1 + Kp • vl), then  [Sf] = [Sf]0/ (1 + Kp • vl).  Thus, the value of 
observed S50, or the midpoint of titration curve, will be reached at the concentration of 
unbound substrate, which is higher by the factor  (1+ Kp • vl) than the true Sf, and the 
true dissociation constants or S50 can be found after correction of apparent dissociation 
constants Sapp by this factor: S = Sapp/(1+ Kp • vl). This correction can be negligible, if Kp 
• vl << 1, as is the case when the volume fraction of the lipid phase is small.  However, 
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at a 3 µM concentration of Nanodiscs vl = 3.3 x 10-4, and for ANF (1+ Kp • vl) = 2, while 
for TST (1+ Kp • vl) = 1.15. 
 
Figure 2.3 Dimensions of a Nanodisc.  Adapted from Baas et al. 2004. 
2.2.9 Data Analysis 
Analysis of the spectral titration of CYP3A4 in Nanodiscs was performed using 
singular value decomposition as described (130, 155).  For each substrate ratio, all 
absorption spectra of CYP3A4 measured between 360 and 500 nm in the presence of 
different substrate concentrations were corrected for the dilution factor and combined 
into the matrix.  For experiments using ANF, the absorption spectrum for the 
corresponding concentration of ANF in 3 µM empty Nanodiscs was subtracted from the 
signal to eliminate interference with the CYP3A4 signal in this region.  Singular value 
decomposition of this spectral matrix revealed that the data are described by two 
spectral components, with the second one corresponding to the difference spectrum of 
low and high ferric CYP3A4.  The third singular value was always less than 5%.  The 
resulting singular concentration vector corresponding to the transition of CYP3A4 from 
low to high spin as a function of substrate concentration was fitted to the Hill equation:  
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aF = Sn/(S50n+Sn) 
where a is the spectroscopic amplitude, F is the fraction of high-spin shift caused by 
substrate binding, S is the substrate concentration, S50 is the spectral dissociation 
constant, and n is the Hill coefficient.  The fitting program was written in MATLAB using 
the Nelder-Mead simplex minimization algorithm implemented in the subroutine 
“fminsearch.m.” 
To detect the presence of heterotropic interaction between two substrates, it is 
necessary to compare the system with the similar reference system where no 
heterotropic cooperativity is present.  In this case, the response of the system does not 
change when one ligand is replaced with another while keeping the total equivalent 
amount of ligands the same.  To account for the difference in absolute affinities of two 
substrates their concentrations are normalized by dividing by the corresponding spectral 
dissociation constants, S50, the concentration corresponding to the midpoint of the dose-
response function.  This allows for the direct comparison of the two substrate 
concentrations in equivalent units in terms of their abilities to independently bind and 
induce a spin transition in the enzyme. 
Using the normalized concentrations of substrates A and B, [A] = A/SA,50 and [B] 
= B/SB,50, the total normalized concentration can be defined as [S] = [A] + [B], and the 
normalized fractions of each substrate as α = [A]/[S], and β = 1-α = [B]/[S].  Such 
normalized coordinates allow for deconvolution of the total response of the system into 
two parts, the first is caused by additive action of two substrates, and the second is due 
to their synergistic cooperative interaction, if present.  The first part may be defined as 
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the linear combination of the fractional contributions of two substrates, R(A,B) = R([S]) = 
αR(A,0) + (1-α)R(0,B).  This response function can be constructed and calculated based 
on two homotropic response functions measured in two separate titration experiments 
with only one substrate at a time, A and B, and used as a reference for experimental 
evaluation of the presence of specific heterotropic cooperativity.  The results of mixed 
substrate titration experiments can be compared with the response calculated for the 
case where there is no synergistic interaction between substrates.  By definition the 
presence of positive heterotropic interactions is manifested in the increase of the 
system response to the simultaneous action of both substrates, as compared to the 
linear combination of responses to their separate actions.  Since the responses of the 
individual substrates include homotropic cooperativity, the linear combination of the two 
responses measured in titration experiments with one substrate at a time will also take 
into account the linear combination of the two homotropic cooperative interactions, and 
thus serve as a reference system for the case of no specific heterotropic cooperativity.  
The non-specific heterotropic cooperativity is indicative of heterotropic interaction 
between two substrates which is equivalent to their averaged respective homotropic 
interactions and thus does not make sequential binding of different substrates more or 
less favorable than would be expected from their corresponding homotropic binding 
constants.  A binding isotherm in the mixed titration experiment for this system will have 
the midpoint substrate concentration: 
s50 = S50 /(αA + (1-α)B) = 1 
In the case of specific positive heterotropic cooperativity, the simultaneous 
binding of different substrates will be more favorable than would be expected from the 
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simple linear combination of separate binding events of those two, and the 
experimentally observed s50 will be less than the corresponding reference value with no 
heterotropic cooperativity, s50 = 1.  Analogously, negative interactions will result in the 
inhibition of the response function, as compared to the reference system with non-
interacting substrates, and experimentally determined s50 > 1. 
 An illustration of such an approach is presented here for the binding of two 
different ligands to a protein molecule with two binding sites.  In the general case, the 
overall occupation of the two sites is represented by the following binding isotherm, Y, 
(209): 
 
Here ctot is the total concentration of the enzyme, represented as the sum of all binding 
intermediates shown in the scheme.  The total fractions of occupied binding sites at 
different concentrations of both substrates are presented in Figure 2.4, as calculated for 
three possible heterotropic interactions between two bound substrates, neutral (A), 
unfavorable (B), and favorable (C).  Calculations have been made for the model which 
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includes homotropic cooperativity for the substrate A (1.2 kcal/mol, corresponding to the 
7.3-fold higher binding constant for the second binding event, α = 7.3) and no 
cooperativity for the substrate B (β=1).  In the first case (Figure 2.4A), a 0.6 kcal/mol 
heterotropic interaction is present between two substrates (γ = 2.7), which is equal to 
the mean arithmetic value of two homotropic interactions (0 and 1.2 kcal/mol).  In this 
case, the population of the mixed intermediate [AB] is equal to the mean geometric 
value of [AA] and [BB], which corresponds to the binding characteristic at the absence 
of specific heterotropic interactions.  Here, where the heterotropic interaction between 
two substrates in [AB] is equal to the geometric mean of the two homotropic interactions 
in [AA] and [BB], the cooperativity in the system may be termed non-specific, because 
the response of the system is identical to the reference system with no heterotropic 
cooperativity.  In such a case, the contour lines of equal height, or isoboles, are straight 
(247-248).  If heterotropic interaction between two substrates is less favorable than 0.6 
kcal/mole (Figure 2.4B), the population of the mixed binding intermediate [AB] is lower 
than statistically expected, and the projections of isoboles are convex, indicating that 
interaction between substrates is unfavorable, or the presence of negative heterotropic 
cooperativity.  For favorable heterotropic interaction greater than 0.6 kcal/mole between 
the substrates (Figure 2.4C), the contour lines are concave as the population of the 
mixed binding intermediate [AB] is higher than is statistically expected, meaning the 
presence of synergistic binding of two substrates, or the presence of positive 
cooperativity. 
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Figure 2.4 Model Binding Surfaces.  In the absence (A), and the presence of negative 
(B) and positive (C) heterotropic cooperativity.  Adapted from Frank et al. 2009. 
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For the mixed substrate titrations at fixed substrate ratio [A]/[T] = α/(1-α),  the 
total concentration of the enzyme with one substrate molecule bound (ANF, or TST) is 
given by: 
c1 = cA + cT = coKA[A] + coKT[T] = coK1([A] + [T]) = coK1[A] + coK1[T] 
where:  KA[A] + KT[T] = K1([A] + [T]) and K1 = (αKA+(1-α)KT) 
Here c0 is concentration of substrate free CYP3A4, KA and KT are the binding constants 
of ANF and TST respectively to CYP3A4. K1 represents the apparent overall 
association constant for both substrates in the mixed system at the given ratio of 
concentrations of two substrates.  K1 is a function of the relative fractions of the two 
substrates determined by the value of α, 0 < α < 1, and their respective association 
constants KA and KT, derived from single substrate binding experiments.  Thus for any 
mixed substrate titration designated as S, the mixture of substrates can be treated as a 
single substrate, as long as their ratio remains constant.  The mixed dissociation 
constant, K1, is represented as a function of concentration ratio of the two substrates.  
In order to account for the different affinities of two substrates, the normalized 
concentration [S] can be defined as: 
[S]/K1 = [A]/KA + [T]/KT 
Similarly for the Hill model with two substrates the mixed affinity can be 
expressed approximately as a function of the individual substrate affinities and their 
ratio (247) utilizing the mixed dissociation constant and accounting for the different Hill 
coefficients of each substrate, 
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Y = αSn/(S50n + Sn) + (1 – α) Sm/(S50m + Sm) 
allowing one to analyze the titration with a mixture of multiple substrates as long as their 
molar ratios remain constant.  To generate the three dimensional spin shift surface from 
the data obtained in mixed titration experiments, the Hill equation fits for TST, ANF, and 
the mixed 1:1, 1:3, 1:5, and 1:10, ANF to TST molar ratios were plotted as a function of 
two variables, namely the normalized concentrations of each substrate, [A]/S50,A and 
[T]/S50,T.  If the observed S50 values for the mixed substrate system remain a linear 
combination of the two single substrate S50 values and the fractions of the substrates: 
S50,S = (αS50,A+(1 – α)S50,T) 
and the normalized spectral dissociation constant is: 
[S]/S50,S = (α([A]/S50,A)+ (1 – α) ([T]/S50,T)) 
then the spectral dissociation constant for the total substrate in the system will remain 
unchanged as the ratio is varied, indicating the absence of specific interactions.  These 
half saturation points plotted along the normalized axes will form a straight line, since 
the normalized S50 = 1 for any substrate ratio, indicating no change in spectral 
dissociation constant. 
If, however, true purely heterotropic cooperativity is observed, the normalized S50 
will not remain constant as the substrate ratio is varied leading to curvature of the half 
saturation contour.  
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2.3 Results 
2.3.1 Single Substrate Titrations 
 One complicating factor of studying ANF spectroscopically with CYP3A4 is that 
the molecule’s absorbance spectrum overlaps with that of the enzyme in the Soret 
region.  One recent attempt to minimize this effect attempted to fix the spectrum at a 
specific wavelength, 390 nm, and measure changes over the rest of the region (241).  
However, this makes the assumption that the spectrum of CYP3A4 is fixed at this 
wavelength, which is not valid.  In the current studies the signal from ANF over the 
Soret region was measured by titrations of ANF into Nanodiscs which contained only 
phospholipids and no CYP3A4.  This signal was then subtracted from the overall 
absorbance spectrum of the titrations of the CYP3A4 Nanodiscs at corresponding 
substrate concentrations as shown in figure 2.5. 
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Figure 2.5 Spectral Titration of CYP3A4 Nanodiscs with ANF.  Top, ANF titration 
into CYP3A4 Nanodiscs.  Middle, ANF titration into plain Nanodiscs.  Bottom, ANF 
titration into CYP3A4 Nanodiscs with ANF signal subtracted. 
Titrations of CYP3A4 Nanodiscs with ANF or TST were monitored by the ability 
of each substrate to induce a Type I spin conversion (figure 2.6).  Fitting to the Hill 
equation yielded an apparent S50 = 44 µM and n = 1.5 for TST, and S50 = 15 µM and n = 
1.8 for ANF, with maximal high spin conversions of 93% and 85% respectively.  A high 
concentration of CYP3A4 Nanodiscs, 3 µM, was used to stabilize the ANF signal within 
the Soret region at high substrate concentrations. Spectral binding constants, corrected 
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for partitioning of ANF and TST into the lipid bilayers of Nanodiscs as discussed in the 
methods, are 38 µM for TST and 7 µM for ANF. 
 
Figure 2.6 Spectral Titration of CYP3A4 Nanodiscs with TST and ANF.  Left, The 
difference spectra and Hill fit of TST.  Right, The difference spectra and Hill Fit for ANF. 
ANF is often treated as an effector molecule for steroid hydroxylation by 
CYP3A4, and has been shown to eliminate observed homotropic cooperativity in these 
reactions (116, 194).  To probe these effects in relation to spin conversion TST was 
titrated in the presence of increasing amounts of ANF (Figure 2.7).  Due to ANF’s own 
ability to induce a high spin transition the starting fraction of high spin CYP3A4 is larger 
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at higher ANF concentrations.  Fitting of these titration curves to the Hill equation 
reveals a decrease in TST homotropic cooperativity, as measured by the Hill coefficient, 
in the presence of ANF and a complete loss of homotropic cooperativity in the presence 
of 25 µM ANF.  While this may suggest that the homotropic cooperativity of TST is 
being replaced with heterotropic cooperativity between the two different substrates, it is 
impossible to separate the additive effects of each substrate’s own ability to induce a 
spin transition in this system. 
 
Figure 2.7 Spectral Titration of CYP3A4 Nanodiscs with TST.  In the presence of 0 
µM (top left), 4 µM (top right), 10 µM (bottom left), and 25 µM (bottom right) ANF. 
2.3.2 Mixed Substrate Binding 
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To deconvolute the additive substrate effects from true heterotropic cooperativity, 
a series of mixed titrations was performed to examine how the spectral dissociation 
constant for the total substrate in the system changes as a function of the substrate 
ratio.  In order to account for differences in each substrate’s ability to induce a spin 
transition the concentrations were normalized by their respective S50 values, as 
calculated from single substrate titrations.  The three dimensional surface of the high 
spin fraction was generated from the series of ANF, TST, and mixed titrations, (Figure 
2.8).  The similar curvature of the surface along the lines defined by equation 
([TST]/S50,TST + [ANF]/S50,ANF) = constant, is revealed by the straight contour lines. The 
latter indicates that, as the ratio of the substrates changes, the relative (or normalized) 
amount of two substrates needed to cause 50% spin-shift remains constant.  Thus, the 
apparently observed stimulation caused by addition of the second substrate is entirely 
due to the higher total substrate concentration in the system and is not the result of any 
additional synergistic interaction between the substrates. 
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Figure 2.8 Spin Surface and Contour Lines Generated From Single Substrate and 
Mixed Substrate Spectral Titrations.  Adapted from Frank et al. 2009. 
 
2.4 Conclusions 
Although heterotropic cooperativity for several CYP3A4 substrate pairs has been 
reported, typically the signal from one substrate is examined while the other is treated 
as an effector (116, 189, 194, 199, 201, 232) and the stimulatory effects referred to as 
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“cooperativity.” However, these approaches fail to address the full landscape of 
interactions, since as in the case of TST, if the first binding event is functionally silent, 
the distribution between the silent and active enzyme states is a function of the total 
substrate in the system, the relative affinities of those substrates, and their molar ratio. 
The addition of a second substrate will drive the equilibrium towards the 
functionally competent states based upon its affinity for the enzyme.  This must be 
taken into account to ensure that the observed changes in the equilibrium distribution 
are due to heterotropic cooperativity and not merely to the trivial additive effect of the 
presence of additional substrate in the system.  We have developed an approach that 
evaluates the total substrate affinity of the mixed substrate system, allowing for the 
detection of heterotropic interactions by using mixed titrations of the substrates at 
various fixed molar ratios.  An equation for mixed substrate affinity can be derived which 
is valid as long as the substrate ratio remains constant.  The mixed affinity is specific for 
a given substrate ratio and also dependent upon the individual affinities of each of the 
two substrates.  Using a series of mixed titrations, a three dimensional binding surface 
can be generated, which reveals changes in enzyme affinity as a function of substrate 
ratio.  The affinity is measured as a result of simultaneous changes in the concentration 
of both substrates, allowing for the detection of the presence of additional heterotropic 
interactions between them, and to separate these interactions from the simple additive 
effect of the simultaneous binding of two different substrates (248). 
This method, which estimates  the synergistic effect of a combination of 
individual agents (248), is based on the comparison of the observed property as a 
function of the overall substrate concentration in a mixed titration experiment 
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(heterotropic titration), in which the ratio of concentrations of two substrates is kept 
constant, with the normalized results of the same titration experiments using pure 
substrates (homotropic titrations).  Using this method, we have systematically studied 
the spin shift caused by TST and ANF taken separately and in different mixtures to 
establish the presence of extra heterotropic interactions between these two substrates. 
The presence of a secondary substrate, such as ANF, does produce an apparently 
stimulatory effect upon TST induced high spin shift in CYP3A4.  However, this effect 
can be attributed entirely to the additive effect of ANF’s own ability to induce a Type I 
spin shift, rather than any true additional heterotropic cooperativity. Thus, the well 
known positive heterotropic effect of ANF on the Type I titration of CYP3A4 by TST 
(116, 197, 241) can be attributed to the additive spin shift caused by ANF binding, and 
not due to some specific favorable interactions between these two substrates, as it was 
suggested previously.  In addition, this method of analysis of extra heterotropic 
interactions is not limited to any particular compounds or to the spectral titration method, 
and can be used also in the studies of steady-state kinetics of product formation. 
  
61 
 
CHAPTER THREE:  CO-INCORPORATION OF CYTOCHROME P450 3A4 AND 
CYTOCHROME P450 REDUCTASE INTO NANODISCS 
 
3.1 Introduction 
 Cytochrome P450 3A4 (CYP3A4) plays an important role in the metabolism of 
xenobiotics and a large number of endogenous compounds in the human liver (21), and 
is the most abundant P450 in this organ (78).  While detailed biophysical 
characterization of some of its soluble superfamily relatives has been accomplished, 
such as cyotochrome P450 101 (CYP101), including the observation of most of its 
reaction intermediates (251), the details of CYP3A4 remain elusive due to its complex 
behavior, including homotropic and heterotropic cooperativity, and the need for specific 
additives to in vitro reconstitution mixtures, and heterogeneity in CYP3A4 sample 
preparations (118, 121-122).  Previous work done to help elucidate the role of substrate 
binding and thermodynamics with CYP3A4 suffers from a wide variability in techniques 
and additives used to reconstitute the in vitro system, leading to some discrepancy in 
the reported kinetic parameters in the literature (124, 129, 140, 155, 186-187, 245). 
 Using Nanodisc technology to self-assemble CYP3A4 into a stable lipid bilayer, 
has allowed for the study of a homogenous monomeric population of the enzyme into a 
native like state (155-156, 240), overcoming many of these previous obstacles.  
However, incorporation of CYP3A4 alone into Nanodiscs only allows for the study of the 
early steps in the catalytic cycle, prior to the transfer of the second electron and 
formation of the peroxo anion intermediate.  Recent work has developed a method of 
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co-incorporation of CYP3A4 and its redox partner cytochrome P450 reductase (CPR) 
into a single Nanodisc, allowing for the study of the functional interactions of the two 
proteins in a catalytically active monodisperse environment (130).  The purification and 
characterization of this system will be discussed here including the Type I spin-
conversion and increase in steady state NADPH consumption rate caused by substrate 
binding. 
 
3.2 Materials and Methods 
3.2.1 Protein Expression and Purification 
 Cytochrome P450 3A4 (CYP3A4) with a histidine affinity tag was expressed from 
the NF-14 construct in the pCW Ori+ vector and purified as previously described in 
section 2.2.1. 
 Membrane Scaffold Protein 1E3D1 (MSP1E3D1) is an MSP protein that has 
been extended by three 22 amino acid alpha helices to form Nanodiscs with a larger 
diameter (153).  It was designed using two previously described proteins, MSP1E3 and 
MSP1D1 (151, 153).  The MSP1E3D1 was cloned into the pET 28 plasmid and 
expressed in BL-21 (DE3) Gold E. coli and purified as previously described in section 
2.2.2.  
 TEV protease with a histidine affinity tag was expressed and purified as 
previously described in section 2.2.3. 
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 Cytochrome P450 reductase (CPR) was expressed using the rat CPR/pOR262 
plasmid, a generous gift from Dr. Todd D. Porter (University of Kentucky, Lexington, 
KY).  Expression and purification of CPR from E. coli was performed using a modified 
procedure previously described (130, 252-253).  The transformed E. coli were plated on 
LB agar plates containing 50 µg/ml ampicillin and incubated at 37° C overnight.  A 
single colony was added to 10 ml of LB media containing 100 µg/ml ampicillin and 
shaken at 220 RPM at 37°C, and grown overnight.  This was used as the starter culture 
for growth in 1 L LB media containing 100 µg/ml ampicillin, and 1 µg/ml riboflavin.  The 
culture was grown at 37°C, shaken at 220 RPM until the OD600 reached 0.8, and was 
then induced with the addition of 1 mM IPTG, and grown for an additional 20 hours at 
33°C, shaken at 220 RPM.  The cells were harvested by centrifugation at 4000 RPM in 
a JA-10 rotor for 15 minutes at 4°C, resuspended in 50 mM Tris HCl, pH 8.0, 1 mM 
PMSF, and centrifuged again at 4000 RPM in a JA-10 rotor for 15 minutes, then frozen 
at -80°C for storage. 
 The pellet was resuspended in 400 ml/L of culture of 75 mM Tris HCl, pH 8.0, 
0.25 M sucrose, 0.25 mM EDTA, 0.02 mg/ml lysozyme at 4°C, then the pellet was 
collected by centrifugation at 4000 RPM in a JA-10 rotor for 30 minutes.  The pellet was 
resuspended in 50 mM Tris HCl, pH 8.0, 1 mM PMSF, on ice, and sonicated using a 
Branson Sonifier 450 set to a duty cycle of 80% and an output of 4 for 30 seconds and 
then allowed to rest on ice for three minutes, for five cycles.  The membrane fraction 
was isolated by centrifugation at 30,000 RPM for 45 minutes in a Ti-45 rotor at 4°C, 
using a Beckman-Coulter L8-55m preparative ultracentrifuge.  The membranes were 
resuspended at 4°C, with 20 ml/L of culture of 50 mM Tris HCl, pH 7.7, 0.1 mM EDTA, 
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0.1 mM DTT, 20% (v/v) glycerol for 1 hour, then 10% (v/v) Triton X-100 was added to a 
final concentration of 0.2% (v/v), and the membranes were stirred at 4°C for an 
additional hour. 
 The membrane fraction was then centrifuged at 30,000 RPM for 1 hour in a Ti-45 
rotor at 4°C, using a Beckman-Coulter L8-55m preparative ultracentrifuge, and the 
pellet was discarded.  The supernatant was applied to a column of 2’5’ ADP agarose, 
equilibrated in 10 column volumes of 50 mM Tris HCl, pH 7.7, 0.1 mM EDTA, 0.1 mM 
DTT, 20% (v/v) glycerol, 0.1% (v/v) Triton X-100.  The column was washed with 10 
column volumes of this equilibration buffer supplemented with 2.5 mM adenosine, and 
eluted with equilibration buffer supplemented with 2 mM 2’ AMP. 
 For detergent removal a DEAE column was equilibrated with 10 column volumes 
of 10 mM Tris HCl, pH 7.7, 0.1 mM EDTA, 0.1 mM DTT, 20% (v/v) glycerol.  The 2’5’ 
ADP agarose column elution was applied to the column, and the column was then 
washed with 5 column volumes of the equilibration buffer, and eluted with equilibration 
buffer supplemented with 0.4 M NaCl.  The yellow fractions were collected and the 
concentration of CPR was determined using an extinction coefficient of 24.1 mM-1 cm-1 
at 456 nm (254), and the specific activity was measured using the cytochrome c activity 
assay as previously described (255).  The samples were then aliquoted and flash frozen 
in liquid nitrogen and stored at -80°C until use. 
3.2.2 Cleavage of Histidine Tag from MSP1E3D1 
 TEV protease cleavage of MSP1E3D1 was performed as previously described in 
section 2.2.4.  The final concentration of cleaved MSP1E3D1 was calculated using the 
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absorbance at 280 nm, and the corresponding extinction coefficient of 26.6 mM-1 cm-1 
(153). 
3.2.3 Co-Incorporation of CYP3A4 and CPR into Nanodiscs 
Assembly of CYP3A4 and CPR in Nanodiscs was accomplished using the larger 
scaffold protein MSP1E3D1 after removal of its histidine tag by cleavage with TEV 
protease, following a modified procedure (130, 252).  The general scheme is shown in 
figure 3.1.  Purified CYP3A4 from the E. coli expression system was solubilized by 0.1% 
Emulgen 913 and mixed with purified CPR in a 1:1.75 molar ratio, and incubated on ice 
for 30 minutes. 
 
Figure 3.1 Schematic for Co-Incorporation of CYP3A4 and CPR into Nanodiscs.  
Adapted from Denisov et al. 2007. 
A disc reconstitution mixture containing MSP1E3D1, POPC, and sodium cholate 
present in 1:135:270 molar ratios respectively was added to the CYP3A4-CPR mixture, 
with a ratio of 10:1 MSP1E3D1 to CYP3A4, yielding an average final ratio of one 
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CYP3A4 per five Nanodiscs.  Detergents were removed by treatment with Amberlite 
beads (1g/ml of final reconstitution mixture), initiating a self-assembly process which 
incorporates the CYP3A4 and CPR proteins into a discoidal POPC bilayer ~12 nm in 
diameter stabilized by the encircling amphipathic MSP1E3D1 belt.  The discs were 
purified over a 5 mL Ni-NTA agarose column, equilibrated in 50 mM potassium 
phosphate buffer pH = 7.4, 0.3 M NaCl, washed with equilibration buffer plus 15 mM 
imidazole, and eluted with equilibration buffer plus 250 mM imidazole.  This removes 
any empty Nanodiscs, or discs containing only a CPR as the histidine tag resides on the 
P450.  Red fractions were pooled and applied to a 5 mL 2’5’ ADP agarose column 
equilibrated in 50 mM Tris HCl, pH 7.4, 0.1 M NaCl, which was then washed with 5 
column volumes of equilibration buffer and eluted with equilibration buffer supplemented 
with 2.5 mM 2’ AMP, eliminating Nanodiscs which do not contain a CPR protein which 
will not bind to this column. 
The eluted Nanodiscs were concentrated and injected onto a Sephadex G-200 
size exclusion column, at a flow rate of 0.5 ml/min, equilibrated in 0.1 M HEPES buffer 
pH = 7.5, 15 mM MgCl2 , 0.1 mM DTT, to remove aggregated proteins.  Fractions were 
individually examined for bromocriptine binding, and those which did not show a ≥85% 
spin conversion at a saturating concentration were discarded.  The remaining pooled 
fractions showed a minimum 90% spin conversion. 
3.2.4 UV-Vis Spectroscopy 
Substrate binding was studied at 1 µM CYP3A4 in Nanodiscs using a Carey 300 
spectrophotometer. Absorption spectra have been measured at 37°C, in 100 mM 
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HEPES buffer pH 7.4, containing 7.5mM MgCl2 and 0.1mM DTT.  The substrates, 
testosterone and α-naphthoflavone, were added from stock solutions prepared at the 
desired molar ratio in methanol, with the final concentration of methanol never more 
than 1%. 
3.2.5 Steady State NADPH Oxidation 
Forty-five picomoles of CYP3A4-CPR co-incorporated Nanodiscs were 
preincubated for 3 minutes at 37˚C, in the presence or absence of substrate, in a 0.6 ml 
reaction volume in 100 mM HEPES buffer (pH 7.4), 7.5 mM MgCl2, 0.1 mM DTT.  The 
reaction was initiated with the addition of 200 nanomoles of NADPH.  NADPH 
consumption was monitored for 5 minutes and calculated from the absorption changes 
at 340 nm using the extinction coefficient 6.22 mM-1 cm-1 for NADPH.   
 
3.3 Results 
3.3.1 Characterization of CYP3A4-CPR Nanodiscs 
After purification of the CYP3A4-CPR Nanodiscs as described in section 3.2.3, 
the pooled fractions were characterized by optical spectroscopy to determine the ratio of 
CYP3A4:CPR in the sample, by comparison to the set of basis spectra for high spin 
CYP3A4, low spin CYP3A4, and CPR (figures 3.2 and 3.3).  The high spin fraction of 
different sample preparations ranged from 1-7% of the total CYP3A4 with an average of 
3%, while the ratio of CYP3A4:CPR varied between 1:2.3 – 1:1, with an average of 
1:1.3. 
68 
 
 
Figure 3.2 Basis Spectra for CYP3A4 and CPR.  The basis spectra for low spin ferric 
CYP3A4 (black) high spin ferric CYP3A4 (blue) and oxidized CPR (red). 
 
Figure 3.3 Fitting of CYP3A4-CPR Nanodiscs.  UV-vis spectrum of CYP3A4-CPR 
Nanodisc (black), and the fit to the basis spectra of the three proteins (red). 
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 To confirm the CYP3A4-CPR Nanodiscs were catalytically active aliquots of the 
sample were tested for the ability to oxidize NADPH in the presence and absence of 
200 µM TST, as described in section 3.2.5.  The presence of a near saturating amount 
of TST stimulates the activity of the enzyme by a factor of approximately four fold (130).  
A linear fit of the change in absorbance at 340 nm, along with the extinction coefficient 
of NADPH 6.22 mM-1 cm-1, allows for the measurement of the rate of NADPH oxidation 
by the CYP3A4-CPR Nanodiscs (figure 3.4). 
 
Figure 3.4 Steady State NADPH Oxidation Rate.  Steady state NADPH oxidation rate 
measured by monitoring absorbance at 340 nm for substrate free (black) and 200 µM 
TST (red) CYP3A4-CPR Nanodiscs. 
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Substrate free NADPH oxidation rates ranged from 17 – 39 nmol/nmol/min, with an 
average of 23 nmol/nmol/min, and in the presence of 200 µM TST, they ranged from 77 
– 158 nmol/nmol/min with an average of 107 nmol/nmol/min.  
3.3.2 ANF Binding to CYP3A4-CPR Nanodiscs 
 It has been previously shown that CYP3A4-CPR Nanodiscs bind TST identically 
to CYP3A4 Nanodiscs as monitored by the heme iron spin state (130).  Spectral 
analysis of ANF binding to CYP3A4-CPR discs, shown in figure 3.5,  was similarly 
identical to that of CYP3A4 Nanodiscs.  Fitting to the Hill equation yielded S50 = 9 µM 
and n = 1.6, for CYP3A4-CPR Nanodiscs compared to S50 = 9 µM and n = 1.8, for 
CYP3A4 Nanodiscs. 
 
Figure 3.5 ANF Titration.  Spectrum of CYP3A4-CPR Nanodiscs shifts from the ferric 
low spin to the ferric high spin state upon the addition of ANF. 
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3.3.3 CYP3A4-CPR Nanodisc Steady State NADPH Oxidation 
 Steady state NADPH oxidation rates were measured for TST and ANF as 
described in section 3.2.5.  For TST the overall trend was similar to previously published 
results (130), but the magnitude was somewhat less, reaching a maximum rate of 188 
nmol/nmol/min at 100 µM TST, as seen in figure 3.6.  This represents a five-fold 
increase over the substrate free rate, as measured for this preparation of CYP3A4-CPR 
Nanodiscs, of 39 nmol/nmol/min.  The general trend followed that of a substrate 
inhibition kinetic model, where later binding events have an inhibitory effect on the 
kinetic behavior of the enzyme (167), as seen by the rapid increase in the oxidation rate 
followed by the slower decline, to 147 nmol/nmol/min that was still a five-fold increase 
over the substrate free NADPH oxidation rate. 
 
Figure 3.6 Steady State Oxidation of NADPH as a function of TST. 
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 As for TST, ANF followed a similar substrate inhibition type curve, peaking 
around 5 µM ANF, at a rate of approximately 60 nmol/nmol/min, followed by a decline to 
38 nmol/nmol/min, as shown in figure 3.7.  However, the response was muted 
compared to TST, with the peak representing a three-fold increase over the substrate 
free rate of 20 nmol/nmol/min, and decline only providing a two-fold stimulation of the 
substrate free oxidation rate. 
 
Figure 3.7 Steady State Oxidation of NADPH as a function of ANF. 
 
3.4 Conclusions  
 Although the co-incorporation of CYP3A4 and its redox partner CPR into a single 
Nanodisc provides a homogenous monodisperse system for the systematic study of 
CYP3A4 kinetics the system has several drawbacks.  Variability in the CYP3A4:CPR 
73 
 
final ratio made results difficult to replicate.  This can be seen in the variability of the 
substrate free steady state NADPH oxidation rate, which was measured as high as 39 
nmol/nmol/min, and as low as 20 nmol/nmol/min.  Low yields from the three step 
purification process (typically <5% of starting CYP3A4), made purifying large quantities 
of CYP3A4-CPR Nanodiscs in a single sample difficult as well. 
 In order to overcome the obstacles working with CYP3A4-CPR Nanodiscs, an 
attempt to add full length CPR to purified CYP3A4 Nanodiscs to reconstitute a 
catalytically active system was made.  Recently Davydov and coworkers have shown 
that the recombinantly expressed reductase domain from CYP102 can interact with 
CYP3A4 to deliver electrons (36), with a reduction rate of 0.037 ± .01 sec-1 for substrate 
free CYP3A4 Nanodiscs (37).  Here, the slowest steady state NADPH oxidation rate 
has been measured at 0.333 sec-1 for substrate CYP3A4-CPR Nanodiscs, which 
represents a lower limit for the reduction rate of CYP3A4 by CPR in the system and is 
still an order of magnitude higher than that reported by Davydov and coworkers using 
the soluble CYP102 reductase domain.  The work with CYP3A4 Nanodiscs and full 
length purified CPR will be discussed in chapter four. 
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CHAPTER FOUR:  GLOBAL ANALYSIS OF HETEROTROPIC COOPERATIVITY 
 
4.1 Introduction 
 In order to circumvent the difficulties working with the CYP3A4-CPR co-
incorporated Nanodiscs and still evaluate the entire catalytic cycle of the enzyme 
purified CPR was mixed with CYP3A4 Nanodiscs to form a functional complex (252).  
This allowed for the observation of spin state, steady state NADPH oxidation, and 
steady state product formation, as a function of substrate concentration under identical 
conditions.  By simultaneously fitting the three data sets to a three site binding model 
the individual parameters for the step wise dissociation constants and state specific 
functional amplitudes can be resolved as has been previously shown with testosterone 
using CYP3A4-CPR co-incorporated Nanodiscs (130). 
 In order to extend the global analysis to the mixed substrate system, ANF and 
TST were first independently analyzed for their own kinetic parameters in the CYP3A4 
Nanodisc and soluble CPR system.  From this analysis it is possible to construct a 
model based on the linear combination of the two substrates’ parameters that yields the 
interaction surface of the two substrates in the absence of specific heterotropic 
interactions between them (247-248).  The model’s predictions were then compared to 
the observed behavior of a mixed substrate system in order to draw conclusions about 
the presence or absence of heterotropic cooperativity.  To examine the effects of 
heterotropic cooperativity, parameters were introduced into the model that influence the 
population of the mixed states relative to the non-mixed states.  The changes in the 
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distributions of the enzyme substrate complexes show how heterotropic cooperativity 
affects the enzyme’s overall behavior. 
 This chapter describes the analysis of the two single substrate systems, the 
mixed substrate system (using a 1:3 molar ratio of ANF:TST), and the construction of 
the non-cooperative reference model. 
 
4.2 Materials and Methods 
4.2.1 Protein Expression and Purification 
 Cytochrome P450 3A4 (CYP3A4) with a histidine affinity tag was expressed from 
the NF-14 construct in the pCW Ori+ vector and purified as previously described in 
section 2.2.1. 
Membrane Scaffold Protein 1D1 (MSP1D1) was cloned into the pET 28 plasmid 
and expressed in BL-21 (DE3) Gold E. coli and purified as previously described in 
section 2.2.2. 
TEV protease with a histidine affinity tag was expressed and purified as 
previously described in section 2.2.3. 
Cytochrome P450 reductase (CPR) was expressed using the rat CPR/pOR262 
plasmid, and expressed and purified as previously described in section 3.2.1. 
  4.2.2 Cleavage of Histidine Tag from MSP1D1 
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TEV protease cleavage of MSP1D1 was performed as previously described in 
section 2.2.4. 
4.2.3 Incorporation of CYP3A4 into Nanodiscs 
 Cytochrome P450 3A4 was incorporated into Nanodiscs using the self-assembly 
process as described in section 2.2.6. 
4.2.4 UV-Vis Spectroscopy 
Substrate binding was studied at 1 µM CYP3A4 in Nanodiscs using a Carey 300 
spectrophotometer. Absorption spectra were measured at 37°C, in 100 mM HEPES 
buffer pH 7.4, containing 7.5mM MgCl2 and 0.1mM DTT.  The substrates, testosterone 
and α-naphthoflavone, were added from stock solutions prepared at the desired molar 
ratio in methanol, with the final concentration of methanol never more than 1%. 
4.2.5 Counter Flow Job’s Titration 
 The counter flow Job’s titration was performed using a modified method as 
previously described (256).  Equal volumes, 600 µL, of either 1 µM CYP3A4 Nanodiscs 
or purified CPR, were placed into the front and rear compartments of a split cell tandem 
cuvette.  The titration was performed by making reciprocal displacements of 20 µL of 
the solutions between the compartments.  Changes in the heme iron spin state were 
monitored by UV-vis spectroscopy and fit to the equation: 
F1,i = F1,i-1(1-vi/V)+(1-F1,i-1)(vi/V); F1,1 = 0 
 Where F1,i is the fraction of the ligand in the first compartment at the i-th step of 
the titration, and vi and V are the volume of the aliquot displaced at the i-th step and the 
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total volume in each of the compartments, respectively.  The fitting program was written 
in MATLAB using the Nelder-Mead simplex minimization algorithm implemented in the 
subroutine “fminsearch.m.” 
4.2.6 Steady State NADPH Oxidation 
Forty-five picomoles of CYP3A4 Nanodiscs were mixed with 157.5 picomoles of 
CPR and preincubated for 3 minutes at 37˚C, in the presence or absence of substrate, 
in a 1 ml reaction volume in 100 mM HEPES buffer (pH 7.4), 7.5 mM MgCl2, 0.1 mM 
DTT.  The reaction was initiated with the addition of 200 nanomoles of NADPH.  
NADPH consumption was monitored for 5 minutes and calculated from the absorption 
changes at 340 nm using the extinction coefficient 6.22 mM-1 cm-1 for NADPH.  The 
reaction was quenched with the addition of 10 µl of sulfuric acid, frozen on liquid 
nitrogen and stored at -80˚ C. 
4.2.7 Steady State Product Formation 
 The frozen samples from the steady state NADPH oxidation experiments were 
thawed and divided into two 450 µl aliquots to which 6 nmol of cortexolone was added 
as an internal standard before extraction against 2 ml dichloromethane.  The samples 
were dried under nitrogen gas, resuspended in 70 µl of methanol, and 50 70 µl was 
loaded onto a Waters Nova-Pak C18 column (2.1 x 150 mm), with a flow rate of 0.5 
ml/min, and linear gradients of 90% buffer A, 95% water, 5% acetonitrile, 0.1% formic 
acid and 10% buffer B, 5% water, 95% acetonitrile, 0.1% formic acid to 40% A at 15 
min, and 33% A at 17 min, and isocratic flow of 33% A to 40 min.  TST and its 
metabolites were monitored at 240 nm and concentrations were determined using the 
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extinction coefficient of 18.9 mM-1 cm-1, and confirmed by comparison to commercially 
available standards for 2β-, 6β-, and 15β-OH TST (130).  ANF and its metabolites were 
monitored at 290 nm and concentrations were calculated using the extinction coefficient 
of  23.7 mM-1 cm-1 (194).  Standards for the ANF metabolites, the 7,8-dihydrodiol and 
5,6-epoxide, were not commercially available, and their identification was surmised from 
published elution profiles and relative elution times (194, 257) (figure 4.1). 
 
Figure 4.1 Elution Profile for Commercially Available Standards. 
4.2.8 Global Analysis Fitting 
 Global analysis for the three site binding model was performed as previously 
described (130), by simultaneously fitting the experimental data sets to the four state 
model shown in Scheme 4.1, where E is the concentration of substrate free CYP3A4, S 
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is the substrate concentration, and ESi is the concentration of the binding intermediates, 
complexes of CYP3A4 with i molecules of substrate bound (i = 0,1,2,3): 
 
Scheme 4.1 
The fractions of the enzyme substrate complexes were expressed using the standard 
binding polynomials, 
     Y = SK1 + S2K1K2 + S3K1K2K31 + SK1 + S2K1K2 + S3K1K2K3 
and the functional properties at different substrate concentrations were represented as 
the linear combination of the fractional contributions from binding intermediates. For 
example, the fraction of the high-spin CYP3A4 in the Type I titrations, YS, is calculated 
as the weighted sum of the signals from the cytochrome P450 molecules with 0, 1, 2, or 
3 substrate molecules bound, having a0, a1, a2, and a3 fractions of high-spin state 
correspondingly:   
     YS = a0 + a1SK1 + a2S2K1K2 + a3S3K1K2K31 + SK1 + S2K1K2 + S3K1K2K3  
For the two site binding model, the final term of the equations were dropped to 
represent the three state binding scheme so that the binding polynomials were of the 
form: 
80 
 
     Y = SK1 + S2K1K21 + SK1 + S2K1K2 
And the equations for the functional properties were given by: 
     YS = a0 + a1SK1 + a2S2K1K21 + SK1 + S2K1K2  
The set of such equations for the spectral titration, NADPH consumption, and 
product formation have been used for the simultaneous fitting of the experimental data 
obtained under the same conditions, using the same set of dissociation constants which 
yeilds a total of twelve parameters.  The fitting program was written in MATLAB using 
the Nelder-Mead simplex minimization algorithm implemented in the subroutine 
“fminsearch.m.” 
4.2.9 Error Analysis 
 A Monte Carlo simulation was used to estimate the statistical errors of the fitted 
parameters.  A normally distributed random error was introduced into each fitted data 
set, using standard deviations of 2% for spin shift, 1 nmol/nmol/min for NADPH 
oxidation, and 0.1 nmol/nmol/min for product formation.  A 67% confidence interval for 
each parameter value from the fits of 200 error-added data sets was used to estimate 
the error (258-259).  The error fitting programs were written in MATLAB using the 
Nelder-Mead simplex minimization algorithm implemented in the subroutine 
“fminsearch.m.” 
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4.2.10 Mixed Substrate Modeling 
 
Scheme 4.2 
The ten state pyramidal binding model (Scheme 4.2), is used for an enzyme 
which can bind up to three total molecules of two different substrates.  It is an extension 
of Scheme 1 which is incorporated along the outer pathways of Scheme 4.2. Binding 
constants KA and KT, represent ANF and TST respectively, and are the same for each 
binding step if there is an absence of intrinsic heterotropic cooperativity, i.e. binding of 
the next substrate molecule may depend on the presence of previously bound 
substrates (KA1 ≠  KA2). Scheme 4.2 also includes three mixed states where the enzyme 
interacts simultaneously with both substrates.  In the case of a titration with a mixture of 
substrates at a constant substrate ratio Scheme 4.2 can be formally represented by 
Scheme 4.1, where S is the total substrate in the system (here, A + T), and the mixed 
82 
 
binding constants, Ki, are given by the average of the respective KAi and KTi, weighted 
against their molar ratio: 
     K1 =  µAKA1 + µTKT1 
    K2 =  µAKA2 + µTKT2 
     K3 =  µAKA3 + µTKT3 
where µA and µT represent the molar fractions of ANF and TST respectively.  Thus each 
ratio of the two substrates can be represented by its own set of mixed binding 
constants, and analyzed based upon the global analysis versus total substrate 
concentration, as if it were a single substrate. 
 The non-cooperative model for the interactions of ANF and TST was developed 
in MATLAB and is shown in figure 4.2.  In the absence of specific interactions between 
the two substrates the binding polynomials and functional properties of the enzyme will 
be equivalent to the linear combination of the two substrates at the given molar ratio. 
The total substrate [S] is equal to the sum of the individual substrates, [A] and 
[T], and µA and µT represent the molar fractions of A and T respectively. 
[S] = [A] + [T] 
µA[S] = [A] 
µT[S] = [T] 
The concentration of enzyme with one substrate bound, c1, is given by the sum 
of the concentrations of the two states of the enzyme with a single substrate molecule 
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bound, c01 and c10.  Here, Ki’s represent association constants for ease of displaying the 
equations. 
c1 = c01 + c10 = EK1[S] = EKA1[A] + EKT1[T] = EµAKA1[S] + EµTKT1[S] 
K1 = µAKA1 + µTKT1 
The concentration of enzyme with two substrates bound, c2, is given by the sum 
of the concentrations of the three states of the enzyme with a two substrate molecules 
bound, c02, c20 and c11. 
c2 = c02 + c20 + c11 = EK1K2[S] = EKA1KA2[A] + EKT1KT2[T] + EKT1KA2[A] + EKA1KT2[T] 
K1K2[S] = µA2KA1KA2[S] + µT2KT1KT2[S] + µTµA(KA1KT2 + KT1KA2)[S] 
K2 = (µAKA1 + µTKT1)(µAKA2 + µTKT2)/K1 
K2 = µAKA2 + µTKT2 
The concentration of enzyme with three substrates bound, c3, is given by the 
sum of the concentrations of the four states of the enzyme with a three substrate 
molecules bound, c03, c30, c21 and c12. 
c3 = c03 + c30 + c21 + c 12 = EK1K2K3[S] = EKA1KA2KA3[A] + EKT1KT2KT3[T] + 
EKA1KT2KA3[A] + EKA1KA2KT3[T] + EKT1KA2KA3[A] + EKT1KT2KA3[A] + EKT1KA2KT3[T] + 
EKA1KT2KT3[T] 
K1K2K3[S] = µA3KA1KA2KA3[S] + µT3KT1KT2 KT3[S] + µA2µT(KA1KT2KA3 + KA1KA2KT3 + 
KT1KA2KA3)[S] + µAµT2(KT1KT2KA3 + KT1KA2KT3 + KA1KT2KT3)[S] 
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K3 = (µAKA1 + µTKT1)(µAKA2 + µTKT2)(µAKA3 + µTKT3)/K1K2 
K3 = µAKA3 + µTKT3 
This allows for binding constants of the mixed substrate system to be evaluated 
according to equation 1, by combining the mixed and non-mixed states for a given 
number of substrates bound into a single state.  In order to simulate specific 
heterotropic interactions, it is necessary to separate the mixed and non-mixed states so 
that: 
K1 = µAKA1 + µTKT1 
K2 = (µA2KA1KA2 + µT2KT1KT2 + γ1µTµA(KA1KT2 + KT1KA2))/K1 
K3 = (µA3KA1KA2KA3 + µT3KT1KT2 KT3 + γ2µA2µT(KA1KT2KA3 + KA1KA2KT3 + KT1KA2KA3) + 
γ3µAµT2(KT1KT2KA3 + KT1KA2KT3 + KA1KT2KT3))/K1K2 
and γ1, γ2, and γ3 represent heterotropic parameters, which indicate favorable (or 
unfavorable) binding for the mixed states relative to the non-mixed states. 
To incorporate functional properties, such as spin transition, the mixed and non-
mixed states may have different functional amplitudes, it is also necessary to for them to 
be considered separately: 
a1K1 = aA1µAKA1 + aT1µTKT1 
a2K2 = (aA2µA2KA1KA2 + aT2µT2KT1KT2 + aM1µTµA(KA1KT2 + KT1KA2))/a1K1 
a3K3 = (aA3µA3KA1KA2KA3 + aT3µT3KT1KT2 KT3 + aM2µA2µT(KA1KT2KA3 + KA1KA2KT3 + 
KT1KA2KA3) + aM3µAµT2(KT1KT2KA3 + KT1KA2KT3 + KA1KT2KT3))/a1K1a2K2 
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where aAi and aTi represent the functional amplitudes from the non-mixed states of ANF 
and TST respectively with i substrates bound (I = 0, 1, 2, or 3), and the mixed state 
amplitudes aMi are given by the average of the non-mixed amplitudes: 
aM1 = (aA2 + aT2)/2 
aM2 = (2*aA3 + aT3)/3 
aM3 = (aA3 + 2*aT3)/3 
 
Figure 4.2 Non-Cooperative Surface and Contours.  Generated in MATLAB.  
Adapted from Frank et al. 2011. 
 
4.3 Results 
4.3.1 Interactions of CYP3A4 Nanodiscs and Purified CPR 
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 In order to probe the interactions of CYP3A4 in Nanodiscs with purified CPR, a 
counter flow Job’s titration was performed as described in section 4.2.5.  This method 
has been used to show the stoichiometry and affinity for CYP3A4 in Nanodiscs with the 
soluble reductase domain of CYP102 (37), by monitoring the shift to the high spin heme 
iron state in CYP3A4 induced by association between the reductase and the 
cytochrome P450.  Fitting the changes high spin CYP3A4 amplitude revealed a 1:1 
complex formation, revealed by the shape of the curve, which corresponds to the 
ascending branch of a traditional Job’s titration, and peaks at F1 = 0.5, with a KD of 130 
nM (figure 4.3), although due to the small overall change in high spin fraction (<10%), 
the previously reported KD of 50 nM measured by size exclusion chromatography may 
be more accurate (252). 
 
Figure 4.3 Counter Flow Job’s Titration Fit of High Spin Amplitude of CYP3A4. 
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4.3.2 Global Analysis of Testosterone and α-Naphthoflavone 
 Simultaneous fitting of the three observed enzyme properties, heme iron spin 
state, NADPH oxidation, and product formation, for each substrate to a three site 
binding model as described in section 4.2.8, allowed for the deconvolution of the 
individual stepwise dissociation constants along with resolution of the fractional 
contributions of the binding intermediates to the overall behavior of the enzyme as a 
function of substrate concentration (figures 4.5 and 4.6).  Attempts to fit the data for 
either substrate to a two site nonspecific model failed, yielding negative values for two 
physiological parameters, the spin amplitude and the product formation rate of the ES 
complex (figure 4.4). 
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Figure 4.4 Global Fitting of ANF Titrations to a Two Site Binding Model. The 
experimental data (red circles) for production formation (B), NADPH oxidation (C), and 
high spin fraction (D), were simultaneously fit to a two site nonspecific binding model, 
resulting in the global fit for each parameter (black lines), and the overall binding 
saturation (A).  The signal from each intermediate, with 0, 1, or 2, ANF molecules bound 
is shown by the black, yellow, and blue, dashed lines respectively. 
The properties of CYP3A4 follow similar trends for both ANF and TST, such as 
the fast acceleration and subsequent drop off in steady-state NADPH consumption with 
increasing substrate concentration.  The binding of ANF is approximately one order of 
magnitude tighter than that of TST, with KD’s of 2, 3, and 7 µM and 27, 46, and 62 µM 
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respectively (table 1).  The binding of the first substrate molecule, forming the ES 
complex, increases the NADPH oxidation rate by several fold for both substrates, to 182 
nmol/nmol/min for TST and 106 nmol/nmol/min for ANF, although it does not induce 
product formation for either.  For TST (22%), but not ANF (4%), this intermediate also 
provides a small contribution to the spin shift.  The binding of the second molecule of 
substrate forms the ES2 complex, opens the product forming pathway of the enzyme 
and further stimulates the NADPH oxidation rate.  For TST, both the NADPH oxidation 
rate and product forming rate are higher than for ANF (344 and 18 nmol/nmol/min for 
TST and 115 and 0.8 nmol/nmol/min for ANF) and it correlates with a large shift to the 
high spin state, 83% for TST, but not for ANF (4%).  The ES3 complex is formed with the 
binding of the third substrate molecule increasing the coupling efficiency (the ratio of the 
product formation to NADPH consumption) by decreasing NADPH consumption rather 
than stimulating product forming rates.  The third ANF binding also induces the Type I 
spin transition (89%) which is observed to occur at the second binding event for TST 
(83%), and is similar upon the formation of the ES3 complex (84%). 
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Figure 4.5 Global Fitting of TST Titrations to a Three Site Binding Model.  The 
experimental data (red circles) for production formation (B), NADPH oxidation (C), and 
high spin fraction (D), were simultaneously fit to a three site nonspecific binding model, 
resulting in the global fit for each parameter (black lines), and the overall binding 
saturation (A).  The signal from each intermediate, with 0, 1, 2, or 3 TST molecules 
bound is shown by the black, yellow, blue, and green dashed lines respectively.  
Adapted from Frank et al. 2011. 
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Figure 4.6 Global Fitting of ANF Titrations to a Three Site Binding Model.  The 
experimental data (red circles) for production formation (B), NADPH oxidation (C), and 
high spin fraction (D), were simultaneously fit to a three site nonspecific binding model, 
resulting in the global fit for each parameter (black lines), and the overall binding 
saturation (A).  The signal from each intermediate, with 0, 1, 2, or 3 ANF molecules 
bound is shown by the black, yellow, blue, and green dashed lines respectively.  
Adapted from Frank et al. 2011.  
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TST KD (µM) 
 
27 
[23 – 35.5] 
46 
[38 – 52] 
62 
[52 – 77] 
 
Spin Shift 
(%) 
NADPH Rate 
(nmol/nmol/min) 
Product Forming Rate 
(nmol/nmol/min) 
E 
 
6±2.0 
- 
42±1.0 
- 
0±0.1 
- 
ES 
 
22 
[17 – 32] 
182 
[159 – 224] 
0 
[0.01 – 0.06] 
ES2 
 
83 
[71 – 91] 
344 
[303 – 375] 
18 
[16.6 – 18.7] 
ES3 
 
84 
[80 – 88] 
115 
[112 – 120] 
18 
[17.3 – 17.8] 
ANF KD (µM) 
 
2 
[1.4 – 3.2] 
3 
[2.3 – 5.1] 
7 
[5 – 8.4] 
 
Spin Shift 
(%) 
NADPH Rate 
(nmol/nmol/min) 
Product Forming Rate 
(nmol/nmol/min) 
E 
 
4±2.0 
- 
36±1.0 
- 
0±0.1 
- 
ES 
 
4 
[4 – 7.8] 
106 
[81 – 140] 
0 
[0 – 0.04] 
ES2 
 
4 
[3.8 – 7.0] 
115 
[89 – 122] 
0.8 
[0.55 – 1.24] 
ES3 
 
89 
[82 – 94] 
41 
[35 – 49] 
0.5 
[0.27 – 0.62] 
 
Table 4.1 Parameters from the Global Fits of ANF and TST.  Adapted from Frank et 
al. 2011. 
4.3.3 Global Analysis of α-Naphthoflavone and Testosterone in a 1:3 Molar Ratio 
 The same trends are followed for the mixed substrate system that were observed 
for each of the functional properties in both single substrate systems, such as the lack 
of product formation coming from the ES complex, and the inhibition of NADPH 
oxidation at higher substrate concentrations (figure 4.7 and table 4.2).  While binding of 
the first substrate triggers an increase in NADPH oxidation rate from 37 nmol/nmol/min 
to 195 nmol/nmol/min, and it is entirely uncoupled resulting in no product formation.  A 
second substrate molecule must bind for the product forming pathway to open, at a rate 
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of 4 nmol/nmol/min and the NADPH oxidation rate decreases to 80 nmol/nmol/min.  The 
third binding event does not significantly alter the rate of product formation or NADPH 
oxidation, but does induce a shift to the high spin state of the heme iron. 
 
Figure 4.7 Global Fitting of Mixed Substrate Titrations to a Three Site Binding 
Model.  The experimental data (red circles) for production formation (B), NADPH 
oxidation (C), and high spin fraction (D), were simultaneously fit to a three site 
nonspecific binding model, resulting in the global fit for each parameter (black lines), 
and the overall binding saturation (A).  The signal from each intermediate, with 0, 1, 2, 
or 3 substrate molecules bound is shown by the black, yellow, blue, and green dashed 
lines respectively.  Adapted from Frank et al. 2011. 
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1:3 Mix KD (µM) 
 
5 
[2 – 6] 
12 
[12 – 19] 
24 
[19 – 24] 
 
Spin Shift 
(%) 
NADPH Rate 
(nmol/nmol/min) 
Product Forming Rate 
(nmol/nmol/min) 
E 
 
12±2.0 
- 
37±1.0 
- 
0±0.1 
- 
ES 
 
13 
[11.7 –14.3] 
195 
[149 – 205] 
0 
[0 – 0.01] 
ES2 
 
12 
[11.7 -14.1] 
80 
[54 – 90] 
4 
[4 – 5.6] 
ES3 
 
103 
[100]* 
87 
[82 – 92] 
3 
[2.3 – 3] 
 
Table 4.2 Parameters from the Global Fits of the Mixed Substrate System.  
Adapted from Frank et al. 2011. 
4.3.4 Global Model of α-Naphthoflavone and Testosterone Interactions with CYP3A4 
 Building upon the linear four state binding models (scheme 4.1) for each 
substrate, a ten state pyramidal model was developed to account for a mixed substrate 
system in which CYP3A4 can accommodate up to three molecules of either substrate 
into the active site (scheme 4.2).  The stepwise binding constants for ANF and TST 
along with functional amplitudes for the outer non-mixed states are given through a 
global analysis of each substrate (table 4.1).  For the three mixed states the average 
values of the non-mixed amplitudes derived from the homotropic global fits have been 
used, as it is impossible to directly measure these properties.  Since this model is based 
upon the linear combination of each substrate’s global fits, it represents a system 
without any specific heterotropic cooperativity, but intrinsically includes each substrate’s 
own homotropic cooperativity, if present. 
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 To test the possible effect of heterotropic interactions, a 1:3 ANF:TST titration 
was simulated with +/-0.6 kcal/mol (at room temperature) of cooperativity for each of the 
three mixed intermediates and compared to the observed data for each of the three 
functional properties (figure 4.8).    This was accomplished by incorporating a 
heterotropic parameter for each of the mixed states to increase (for positive 
cooperativity) or decrease (for negative cooperativity) their populations in the model 
relative to the non-mixed states.  The effect of introduced heterotropic interactions on 
the spin shift is apparent only at lower substrate concentrations.  This is explained by 
examining the intermediate populations for simulated cooperativity.  Positive 
heterotropic interactions skew the populations of enzyme-substrate complexes towards 
the more fully saturated mixed states, while negative interactions have the opposite 
effect.  The contribution from the functionally silent ES complex is increased in 
simulated negative interactions relative to positive ones.  The contribution of the ES2 
complex increases at lower substrate concentrations in the presence of the simulated 
positive heterotropic interactions.  Even in the presence of negative interactions, the 
contribution of the ES3 complex is so dominant at high substrate concentrations that the 
effects of simulated heterotropic cooperativity are minimized in this region. 
The heterotropic interactions would show the largest effect on product formation 
if present.  This is due to the fact that the product formation is dominated evenly by 
contributions from the ES2 and ES3 complexes, which encompass the mixed substrate 
complexes where heterotropic interactions are maximized.  The effects of the added 
heterotropic cooperativity for NADPH oxidation are muted due to the larger contribution 
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of the ES complex and smaller contribution of the ES3 complex to the overall oxidation 
rate, relative to product formation. 
 
Figure 4.8 Simulations of Functional Properties for the Mixed Substrate System.  
In the presence of positive (green dashed line), negative (blue dashed line), or no (black 
solid line) heterotropic cooperativity.  Experimental data shown by red circles. 
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4.4 Conclusions 
 In the absence of cooperativity the stepwise dissociation constants should 
conform to the expected statistical ratio for the three site binding model K1 = K2/3 = K3/9 
(scheme 4.1) (123).  The ΔΔG’s between the sequential binding events can be 
calculated in comparison to the non-cooperative binding ratio where ΔΔG12 = -
RT·ln(3·K1/K2), and ΔΔG23 = -RT·ln(3·K2/K3).  For ANF they are -0.4 and -0.2 kcal/mol, 
and -0.3 and -0.5 kcal/mol for TST (figure 4.9).  Similarly for the mixed substrate 
system, the dissociation constants of 5, 12, and 24 µM  (table 4.2) fall in between those 
of ANF and TST, and calculating the ΔΔG’s between the binding events gives -0.2 and 
0 kcal/mol of heterotropic cooperativity (figure 4.9), confirming the results of the 
simulation that there is no heterotropic cooperativity in the system.  These values are 
smaller than RT = 0.6 kcal/mol at room temperature, which means that there is virtually 
no deviation from purely statistical behavior for binding of these substrates. Because of 
essentially non-cooperative binding, the observed deviations from Michaelis behavior 
and apparently cooperative properties of the enzyme arise from differences in the 
fractional contributions of the enzyme-substrate complexes to their experimentally 
observed functional properties and are not due to an uneven distribution of the 
complexes themselves. 
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Figure 4.9 Cooperativity of Binding Events in the Single Substrate and Mixed 
Substrate Systems. 
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CHAPTER FIVE:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Conclusions 
 Cytochrome P450 3A4 (CYP3A4) is the most abundant hepatic P450 (21), and 
capable of metabolizing approximately half of the most commonly prescribed drugs 
(87).  Its atypical (non-Michaelis) kinetics have been well established in the literature 
(121-122), as well as its ability to interact with multiple substrates simultaneously (123, 
246).  As a result, CYP3A4 has become an important focus for its potential to mediate 
drug-drug interactions (78, 89).  These atypical behaviors fall into two categories; 
homotropic cooperativity, when molecules of the same substrate interact, and 
heterotropic cooperativity. 
 Understanding how homotropic cooperativity arises in this system was recently 
studied in detail by the Sligar laboratory (130, 155).  Incorporation of CYP3A4 into 
Nanodiscs enabled detailed observation of the enzyme’s functional properties in a 
homogenous, monodisperse system, avoiding the ill-defined higher order oligomeric 
interactions which lead to enzyme heterogeneity in microsomes (133), and the 
detergent effects observed in purified reconstituted systems (150).  By globally fitting 
multiple functional properties of the enzyme, including heme iron spin state, NADPH 
oxidation rate, and product forming rate, to a three site binding model it was possible to 
resolve the individual step wise dissociation constants and state specific functional 
amplitudes for testosterone (130).  Although homotropic cooperativity for TST has been 
well reported in the literature (116, 118, 127, 155, 185-187), it was shown that the 
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apparent homotropic cooperativity for this substrate was not due to any increase in 
binding affinity, but rather due to a functionally silent enzyme substrate complex (123, 
130).  The binding of the first molecule of TST to the enzyme fails to open the product 
forming pathway, nor does it perturb the spin equilibrium, making these properties 
appear cooperative due to the increased influence of the second and third binding 
events on the overall dose-response curve. 
 ANF is another substrate of CYP3A4, which has also been reported to display 
homotropic cooperativity (187, 189-190), as well as heterotropic cooperativity with TST 
and other substrates (137, 163, 194).  In the work shown here we have applied the 
global analysis previously performed for TST to ANF, showing that it too has little 
binding cooperativity, and the observed apparent cooperativity is likewise derived from a 
functionally silent first binding event, which shifts the dose-response curve’s signal to be 
more dependent upon the subsequent two binding events. 
 We further developed the global analysis to incorporate an analysis of the 
possible heterotropic cooperativity between these two substrates.  This model is based 
upon the fact that in the absence of heterotropic cooperativity the signal from dose-
response curve for a given ratio of the two substrates will be equivalent to the linear 
combination of the two individual dose-response curves for the corresponding ratio 
(247-248).  Heterotropic parameters included within the model allow for the simulation 
of heterotropic cooperativity to examine its effects in the system.  By comparing the 
observed behavior of the enzyme in response to a mixture of ANF and TST to that 
which is predicted by the model it can be shown that these two substrates do not 
behave cooperatively. 
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 This method of analysis, the global deconvolution of heterotropic interactions, 
allows for an easier means of observing heterotropic interactions than previously 
proposed more complex models (167).  It is independent of the binding model used, 
working for two-site, three-site and Hill analyses of the dose-response curves, as well 
as the observed behavior being modeled:  spin state, NADPH oxidation rates, or 
product forming rates. 
 
5.2 Future Directions 
 The work presented in this thesis shows that for the specific substrate pairing of 
ANF and TST there is no heterotropic cooperativity in the system, and homotropic 
cooperativity is purely the result of different functional amplitudes arising from the 
various enzyme substrate complexes in solution.  However, it remains to be shown if 
this is a general property for all CYP3A4 substrates which display “drug-drug” 
interactions or if it is specific to these two.  Additionally, it remains to be determined if 
other cytochromes P450, such as CYP2C9, where heterotropic interactions have been 
reported (246), are also truly cooperative, or if the observed cooperativity is likewise an 
artifact of the method of the analysis of the system. 
 It is also well known that the lipid membrane bilayer is heterogeneous in vivo, 
consisting of a variety of charged and neutral phospholipids which alter the local 
membrane environment’s properties (260).  The presence of anionic phospholipids has 
been observed to stimulate the activity of CYP3A4 (261-262), possibly through aiding 
interactions between CYP3A4 and CPR for efficient electron delivery (263).  Nanodiscs 
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provide a method of generating a local membrane environment of controlled lipid 
content (264-265), and would make a useful tool for understanding lipid-protein effects 
that avoid the complications associated with larger lipid bilayer systems, such as 
liposomes, which are difficult to prepare with precisely controlled size and lipid 
stoichiometry. 
 Work has also been performed to adapt CYP3A4 Nanodiscs into a high 
throughput screen to test substrate binding by methods such as localized surface 
plasmon resonance spectroscopy (266).  Coupling the global deconvolution and mixed 
substrate analysis techniques described in this work to a high throughput screening 
system would likely allow for the rapid determination of drug-drug interactions due to 
heterotropic cooperativity in the various drug metabolizing cytochromes P450, and 
would be of benefit to the pharmaceutical industry and the development of safer 
therapeutics. 
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